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Abstract
Optimizing the delivery of pre-transplantation therapies during
normothermic machine perfusion of human kidneys
Jenna DiRito
Despite a severe organ shortage, thousands of kidneys from higher-risk donors go unused
each year. These marginal kidneys have an increased susceptibility to ischemia reperfusion
injury and the use of these organs may ultimately result in post-transplant complications like
graft loss and recipient death. Normothermic machine perfusion has emerged as a platform
for ex vivo assessment and repair to increase utilization of higher-risk donor organs without
increasing risk to the recipient. This system also allows for the study the pathophysiology
of human kidneys exclusively. After developing an understanding of how marginal kidneys
behave during periods of controlled perfusion, one can then rationally design pre-transplant
therapies to be delivered in isolation on the ex vivo circuit.
Through this body of work I have discovered (1) that it is possible to deliver vascular-targeted
nanoparticle therapies during normothermic machine perfusion of human kidneys. I have
shown that while nanoparticles may accumulate nonspecifically in red cell plugs, I have (2)
identified the cause of and cleared the microvascular obstructions within a human kidney
using a regimen of tPA and plasminogen. Having re-established microcirculation within a
kidney not only improves drug delivery, but also allows for more homogenous oxygen and
nutrient delivery, leading to a more viable organ. After having shown that nanoparticles can
effectively delivered within this system following tPA and plasminogen treatment, I began
to explore which therapeutics to deliver. I have (3) demonstrated that delivering an NLRP3
inhibitor during normothermic machine perfusion helps protect the organ from ischemia
reperfusion injury. Finally, I have also (4) developed tools utilizing contrast-enhanced
computed tomography to more holistically evaluate the vasculature of the entire kidney
when assessing the efficacy of therapeutic approaches. This work almost exclusively utilized
human kidneys that were deemed unsuitable for transplantation. Studying the exact specimen
I am looking to repair has allowed me to develop highly translational therapeutic approaches
that I believe can help improve marginal kidney utilization.

To my (not so) little brother, Nicky.
You are the reason I’ve smiled throughout this entire journey.
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Introduction
The state of renal transplantation
Transplantation is the best available treatment for end stage renal failure, but a worldwide
shortage of donor kidneys has resulted in a significant gap between the number of transplants
performed versus patients in need [1]. In the U.S., there are currently ~93,000 people waiting
for a kidney, but only ~20,000 transplants are conducted annually [2]. This lack of access to
transplantation leads to an average of 13 deaths on the kidney waitlist per day. In the same
24-hour period, ~10 donated kidneys are declined for transplant and ultimately discarded
without clinical use typically due to concerns over post-transplant complications associated
with organs from higher-risk donors [3, 4]. High-risk kidneys are believed to be more
susceptible to ischemia reperfusion injury (IRI) as compared to standard criteria kidneys
and are believed to have worse clinical outcomes, resulting in the limited utilization of these
‘marginal’ organs [5, 6]. The discard rates of kidneys from the donors believed to be highest
risk—as determined by the Kidney Donor Profile Index or KDPI—can reach as high as
50-75% [7]. However, the continuing decline in the health of the organ donor population
(e.g. increasing age, obesity) suggests that discarding all less than optimal organs is not a
viable long-term strategy [4, 8–10]. There remains a need for new pre-transplant therapies to
address the increased risk associated with transplanting marginal organs. Moving forward,
comprehensive therapeutic strategies must be developed to protect high-risk kidneys from
IRI in order to increase utilization of these organs.
Renal ischemia reperfusion injury
Clinically, IRI is defined as a sudden period of disrupted blood flow followed by the restora-
tion of an oxygenated blood supply [11]. Histologically, IRI results in tubular necrosis,
endothelial and epithelial damage, widespread inflammation, loss of structure, and cyst
formation [12]. An ischemic organ will also typically have reduced metabolic function and
microvascular damage. Post-transplant IRI can result in acute kidney injury manifested as
xxvi Introduction
delayed graft function, which may ultimately impact long term graft survival [13, 3]. The
severity of IRI can worsen depending on cytokine release at the time of death of the donor
and through issues in general management of the organ resulting from the complex logistical
nature of transplantation [6].
It is imperative to understand the components behind IRI to develop an appropriate treatment.
IRI is a multifactorial process that is a result of the restoration of normoxic conditions
following transplantation [6, 14]. This injury results in a dynamic process of neutrophil
activation, increased production of cytokines, expression of adhesion molecules, and release
of reactive oxygen species (ROS), resulting in inflammation and cellular necrosis [14, 15].
A critical mechanism in IRI that is explored in this thesis is the intracellular assembly
and activation of the NLRP3 inflammasome, which triggers production of inflammatory
caspases and the maturation of the prototypic inflammatory cytokine IL-1β and IL-18 [16–
18]. Inhibition of the NLRP3 inflammasome has been proposed as a therapy to prevent IRI,
but has yet been tested in relevant human models [18–20]. Although progress has been made
in animal model systems, clinical translation remains a challenge.
To date, only a handful of clinical trials have started to investigate methods of ameliorating
IRI (NCT00298168, NCT01442337, and NCT00802347). However, these clinical trials
did not replicate the same successful outcomes previously demonstrated in rodent models.
All the studies in question have faced similar challenges associated with systemic drug
delivery and have been discontinued [21] . Traditionally, treatments for IRI (as well as
for most other renal diseases) are delivered systemically following transplantation [22, 23].
The primary challenge of the systemic delivery stem is largely driven by the mononuclear
phagocyte system (MPS). The MPS consists primarily of monocytes and macrophages
present in the liver, spleen, and lymph nodes. This system works to remove foreign bodies,
which can include therapeutics, from the circulation, and this often limits the effectiveness
of systemically administered drugs [21]. Thus, there remains a significant need for highly
specific renal therapies that can overcome the challenges of systemic delivery and adequately
alleviate IRI.
Normothermic machine perfusion of human kidneys
Normothermic machine perfusion (NMP) has emerged as a modality for pre-transplant
revitalization of marginal organs with the goal of improving utilization without increasing
recipient risk [24, 25]. Leading centers in the UK, Canada, The Netherlands, and the
United States have all begun to move NMP technology forward (Table 1)[26–28]. In the
xxvii
current clinical practice of NMP, blood flow is re-established throughout the organ using
serum-depleted red-blood-cells (RBCs) at or near body temperature for 1 hour prior to
transplantation [26]. This approach has been established as a safe clinical procedure and
has now been employed routinely in clinical practice in the U.K. [26]. Though the precise
mechanism of potential benefit is still under investigation, this period of NMP facilitates
functional assessment of the organ (e.g. hemodynamics, urine production) to allow surgeons
to reconsider organs that had previously been deemed unsuitable for transplantation [24, 25].
This approach also allows aspects of the reperfusion phase of ischemia-reperfusion injury to
happen in a controlled ex vivo setting rather than a sick patient, which may provide additional
benefits. Preliminary results in a small series of kidneys from older deceased donors in the
UK suggested that NMP may reduce DGF rates [24, 25]. A multicenter randomized control
trial is currently underway (ISRCTN15821205) to directly assess if there are clinical benefits
relative to standard cold preservation in kidneys donated after cardiac death (DCD) [26].
Delivering therapeutics on an ex vivo circuit
It is possible that NMP can improve some of the deleterious effects of IRI on its own,
perhaps by a pre-conditioning mechanism in the setting of a protective, closely monitored
environment [24]. In addition to these benefits, NMP serves as a platform to deliver potential
treatments to further IRI treatments. NMP presents a unique opportunity to deliver therapies
in isolation from the phagocytic system that rapidly eliminates systemically delivered drugs
from circulation. Any treatments administered during NMP have direct contact with the
organ vasculature and avoid most complications derived from systemic delivery [29]. NMP
is being rapidly utilized as a device to deliver therapies within an opportunistic window in
an attempt to reduce the injurious effects of ischemic injury [30, 31, 31, 32] . A handful
of therapies, although not directly tested in human kidney NMP, have begun to emerge as
promising treatments to protect renal grafts from complications of transplantation (Table 1).
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xxxii Introduction
Perfusate composition
Although major deviations from the original perfusate used by Hosgood et al have yet to be
implemented, optimizing perfusate conditions may be a critical step in ensuring properly
reconditioned organs. Vasodilators, anti-inflammatory and anti-hypertension drugs, insulin,
glucose, and a nutrient solution are delivered during clinical cases of renal NMP to help
establish strong renal blood flow and better prepare the kidney. Yet, there have been no
studies examining the necessity or benefit of these additions to the perfusate. Other groups,
have begun to investigate acellular perfusates such as Hemopure, a synthetic hemoglobin-
based oxygen carrier, during NMP of human kidneys as a safe but more logistically feasible
alternative to red blood cell based perfusates [33]. With the emerging literature on the benefits
of NMP, it may be impactful for a study to be conducted that systematically examines and
optimizes perfusate composition, to maximize all therapeutic results from NMP.
Gases
As a baseline, 95% oxygen is delivered during NMP and rates of oxygen consumption are
used to measure the health of the organ [26, 34]. Oxygen consumption is maximized at
normothermic temperatures, making NMP an ideal system for reconditioning. Nevertheless,
there are other gases that, when delivered at low doses, have shown some evidence of having
protective effects in the kidney. Carbon monoxide, nitric oxide, and hydrogen sulfide have
all been investigated as therapeutic agents to protect against IRI, promote vasodilation, and
inhibit apoptosis [30, 31, 35] . Both carbon monoxide and hydrogen sulfide have been shown
to inhibit IRI throughout early functional outcome measures in porcine kidneys during NMP
[35, 30]. Because gases can be easily absorbed into the blood, they work as ideal therapeutics
in this closed, circulating system. Although little work has been done in clinically relevant
systems for renal transplant, expanding and translating this work to a human model may offer
kidneys additional benefit and protection prior to transplantation.
Stem cell therapies
Mesenchymal stromal cells (MSCs) can adapt to their microenvironment and differentiate
into several different lineages, all while locally releasing a range of modulatory cytokines[36].
After encouraging results from animal studies, MSC administration has been adapted for pre-
clinical studies, delivered via intravenous infusion after renal transplantation[36]. Although
there were no adverse effects noted from these studies, MSCs were shown to be trapped in
lung microcapillaries and could not reach the kidneys [36]. When delivered using isolated
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perfusion circuits, MSCs have been showed to reduce inflammatory cytokine production
and promote renal regeneration [37]. This approach has the potential to serve as a critical
pre-transplantation therapy to repair ischemically damaged kidneys and is currently planned
to undergo pre-clinical trials [37].
Gene therapies
The prospect of altering gene expression in isolated organs ex vivo opens the door for more
effective, personalized therapies. In porcine models of ex vivo lung perfusion, adenoviral
vector delivery has been demonstrated to be safe and effective [32]. This therapy resulted in
a decreased inflammatory response with better graft functionality after transplantation [32].
In the area of renal research, Brasile et al previously demonstrated the ability to target an
exogenous gene to the vascular endothelium of a kidney during NMP in a proof-of-concept
experiment [38]. To protect the graft from complications of transplantation, gene therapies
can be tailored for HLA silencing or to block transcriptional mechanisms of IRI. Introducing
other methods of genetic manipulation, for example, siRNA, into the perfusate may require
the utilization of stable vehicles for delivery.
Nanoparticles have properties that make them ideally suited to this role [39]. In contrast
to other theorized treatments, nanoparticles have long-lasting effects and well-established
slow-release profiles that extend beyond the period of normothermic perfusion [39]. Any
drug that is typically delivered systemically can also be introduced during NMP for more
concentrated, short-term treatments [29]. However, when treating IRI, a more prolonged,
protective action is desired, as its effects persist long after the initial period of perfusion after
transplantation. Each theorized therapy for this system has its own setbacks. What is needed
is a modular system that can work across multiple mechanisms of IRI for an extended period
[29].
Targeted nanoparticle therapies
Polymeric nanoparticles (NPs) have a long history of safe use in humans as drug delivery
vehicles for the treatment of a wide variety of diseases [40, 41, 7] One of the primary benefits
of NPs is their modularity. The polymer type can be varied to enable encapsulation of various
classes of therapeutics from small molecules to nucleic acid–based drugs [7, 42]. In addition,
NPs can be formulated to provide sustained therapeutic release with the rate of release
controlled by polymer molecular weight. Finally, the polymer surface can also be modified
in a variety of ways to suppress unwanted cellular interactions and/or enhance association
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with a target cell type. Despite all the potential of NP drug carriers, clinical translation
remains a challenge, largely due to issues with controlling NP localization following systemic
administration.
Following systemic delivery, most varieties of NPs are rapidly eliminated via phagocytes
in the liver and spleen (via the aforementioned MPS) [43]. This results in a relatively low
accumulation of NPs at the desired site of therapeutic delivery and creates the potential for
off-target toxicity [44]. To achieve higher accumulation at sites of disease, NPs have more
recently been manufactured to have “stealth” properties in order to evade the immune system
and thereby extend circulation times [45]. However, this method is not entirely effective
and can still result in relatively short circulation half-lives and high levels of off-target
accumulation.
Another popular strategy utilized in an attempt to introduce more reliable anatomic specificity
is “molecular targeting.” This approach employs conjugation of ligands to the NP surface,
with the ligand selected on the basis of specificity for a receptor expressed on the target
cell type of interest. Although this strategy seems logical, it is important to note that the
forces that govern ligand- receptor interactions (e.g. hydrogen bonds, electrostatics) only
operate over a distance of ~0.3-0.5 nm [46]. Thus targeting is not capable of equipping NPs
with a capacity to “home” to sites of interest, but rather can only enhance the likelihood
that an NP will be retained by a cell it happens to contact [47, 40, 41, 29] Consequently,
molecular targeting has not been a reliable approach for controlling the anatomic localization
of systemically administered NPs.
Although enhanced retention through the conjugation of ligands may not always be effective
in systemic delivery, it is in many ways perfectly suited for an isolated NMP setting [41, 40,
29]. In the context of an isolated organ, NPs can largely avoid the challenges associated with
systemic delivery [29]. An oxygenated plasma-free red cell solution is used to perfuse the
organ, which obviates any complications that may arise from opsonization by serum proteins
or tissue-resident phagocytes. Moreover, studies have shown that targeting will typically lead
to internalization of NPs, which then provides an intracellular depot effect for effective drug
delivery [48].
Whole organ assessment
To properly assess the efficacy of a therapeutic treatment, more comprehensive diagnostic
tools must come to fruition. Although the number of marginal kidney transplants has
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increased, there has been little progress in the development of a rigorous quality assessment
for marginal kidneys. Currently, NMP also allows one to monitor the organ and assess
its quality [27]. Outcome measures typically include renal blood flow, urine output, mean
arterial pressure, oxygen consumption, creatinine clearance, ion concentrations, metabolic
markers, and histologic analysis [49, 27]. A variety of biomarkers are assessed to determine
the health of the organ, but a specific biomarker for IRI has yet to be identified. Most of
these measures are providing clinicians with only superficial, regional information. It is
likely that the quality of a perfusion is not uniform throughout the entire organ and that
biopsies may only give insight into a certain section of the tissue. Additionally, biopsies
are invasive measures that may impact the quality of organ perfusion. Measures like renal
blood flow may not accurately describe the quality of microvascular perfusion. High urine
output measurements may falsely signify a well-functioning kidney when the organ has lost
its ability to properly concentrate urine. To more accurately gauge how well a kidney has
reperfused, and how therapies are affecting the microenvironment, one must be able to look
inside of the organ, non-invasively.
Throughout this thesis I have aimed to:
1. Effectively deliver targeted nanoparticles during ex vivo NMP 2. Re-establish microvascu-
lar circulation in poorly perfused organs 3. Understand mechanisms by which microvascular
obstructions arise 4. Investigate potential pre-transplantation therapeutic strategies to prevent
IRI 5. Develop non-invasive imaging methods to visualize perfusion quality of whole organs
I propose that this work, if adopted in clinical practice, will lead to the increased utilization
of marginal kidneys for transplantation.

Chapter 1
Delivering targeted nanoparticles during
normothermic machine perfusion
NMP creates a window of opportunity for the ex vivo delivery of therapeutic agents to further
alter the graft microenvironment directly in the transplanted organ. In particular, the endothe-
lial cell (EC) lining of the graft vasculature - the primary target of graft injury due to ischemia
reperfusion or preformed anti-donor antibodies (Ab) [50–54] - is directly accessible to the
perfusate during NMP. Reduction of preformed Ab by plasmapheresis or immunoadsorption,
sometimes in combination with administration of intravenous immunoglobulin, may partially
mitigate early Ab-mediated rejection [55]. However, these approaches are expensive, and
neither strategy has been fully successful on its own. Ex vivo treatment of the vascular EC
targets in the isolated graft (rather than the organ recipient) may represent a complementary
strategy to enhance efficacy and minimize adverse systemic effects.
Because the nature of the host’s adaptive immune response can evolve over the first few
postoperative weeks, a prolonged therapeutic response over this time period will likely be
needed. It has previously been shown that drugs encapsulated within polymeric nanoparticles
(NPs) can be internalized by human ECs and that these NPs can serve as a slow release depot
for drug delivery because the NPs slowly degrade by hydrolysis [56]. In the case of a small
interfering RNA (siRNA), the therapeutic effect may persist 6 weeks or longer [7]. The
challenge I address in this chapter is how to best ensure that NPs introduced during NMP are
efficiently delivered to graft ECs.
Targeted NPs have thus far had only limited success in clinical medicine because of several
challenges associated with systemic administration [39, 57]. First and foremost, NPs typically
cannot efficiently escape from the vasculature to reach extravascular targets [58]. This
results in marked accumulation within phagocytes of the liver and spleen that compete
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nonspecifically with the intended target cell [59]. In addition, surface adsorption of serum
proteins can create a so-called “protein corona” that can mask targeting ligands and abolish
targeting benefits in vivo [60–62]. Targeting graft ECs during NMP, which uses a serum free
perfusate, can potentially circumvent these challenges.
In this chapter, I show that conjugating anti-human CD31 Ab to poly(lactic acid)-poly(ethylene)
glycol (PLA-PEG) NPs loaded with a fluorescent dye and administering them to isolated
human kidneys during ex vivo NMP can lead to enhanced vascular retention compared to non-
targeted NPs. Using two-color quantitative microscopy on cryosectioned biopsies, I observed
the time-dependent accumulation of CD31-targeted and nontargeted NPs simultaneously in
physiologically viable human kidneys during a period of NMP. This approach showed that
Ab targeting to ECs can produce enrichment of accumulation in both renal glomerular and
interstitial microvascular ECs in regions that were well perfused.
1.1 Identifying endothelial surface markers on human kid-
neys
To evaluate the potential use of molecularly targeted NPs for use during ex vivo perfusion
of the human kidney, I first sought to identify a suitable surface protein on ECs to target.
CD31, also known as platelet EC adhesion molecule–1 (PECAM-1), is a pan-EC marker
typically expressed at relatively high quantities [63]. Although it is also expressed on platelets
and new thymically released T cells, neither of these potentially competing cell types are
present in isolated kidneys that are perfused with leucocyte-depleted and washed red blood
cell (RBC) suspensions. CD31 has been shown to be a viable target to facilitate binding
and subsequent internalization of Ab-conjugated NPs within ECs [64–66], provided that
an appropriate epitope is recognized by the conjugated Ab [64]. These features suggest
that CD31 may be well suited as a receptor for targeting of Ab-NPs uniformly to human
renal ECs. However, the renal cortex contains a variety of vascular beds—including arteries,
afferent and efferent arterioles, glomerular capillaries, peritubular capillaries, venules, and
veins—that are molecularly distinct and may vary in the quantity of CD31 expressed (Figure
1.1A). To confirm the appropriateness of CD31 as the target, I probed for the expression of
CD31 throughout the renal cortex of three separate human donor kidneys using fluorescence
immunohistochemistry. CD31 staining was consistently present throughout the vascular
beds of the renal cortex, suggesting that CD31 is an EC receptor with the potential to induce
widespread accumulation of targeted NPs (Figure 1.1B and C).
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Fig. 1.1 CD31 is present throughout the human renal vasculature. (A) Representative
fluorescent immunohistochemistry staining image of a cryosection taken from a wedge biopsy
of a human kidney undergoing normothermic machine perfusion (NMP). Section was stained
for Ulex to depict vascular endothelium (green). White arrows label different vascular beds
and the kidney surface. Multiple 20× images were tiled to reconstruct the entire cryosection.
(B) Representative images for CD31 (green) and nuclear 4’,6-diamidino-2-phenylindole
(DAPI; blue) staining of glomerular capillaries (left) and interstitial microvessels (right).
Representative staining from three different donor kidneys
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1.2 Targeted nanoparticle kinetics in vitro
I used nanoprecipitation to assemble NPs from a block copolymer of PLA-PEG (Figure
1.2A). This approach produces monodispersed NPs with an inert surface coating that reduces
NP clumping [67] and thereby decreases the likelihood that aggregates of NPs might plug
vessels and interfere with graft function. In addition, the PEGylated surface allows Ab to be
conjugated using simple standard approaches [68]. NPs encapsulating either 1’-dioctadecyl-
3,3,3’,3’-tetramethylindocarbocyanine perchlorate (DiI) or 3,3’-dioctadecyloxacarbocyanine
perchlorate (DiO) dye were about 165 to 170 nm in diameter with a polydispersity index (PDI)
of <0.15 by dynamic light scattering (DLS; Figure 1.2B). Dyeloaded NPs were conjugated
to either an anti-CD31 (CD31-NPs) or a nonbinding isotype-matched Ab (Control-NPs)
via covalent coupling to terminal COOH end groups on the PEG. CD31-NPs strongly
associated with HUVECs, whereas Control-NPs showed minimal association (Figure 1.2C).
Quantification of this association via flow cytometry demonstrated that CD31-NPs enhanced
accumulation by about 80× relative to Control-NPs under these static incubation conditions
(Figure 1.2D and E).
Although targeted NP association in static culture is frequently used as a measure of potential
for targeting in vivo [56], its relevance is unclear because association of NPs with ECs in the
vasculature will occur under flow. The kinetics of targeted NP association with ECs are likely
influenced by both the presence of flow and NP concentration. These features are particularly
relevant for clinical NMP, given the relatively short perfusion period (typically about 1
hour). Thus, I quantified the targeting kinetics of CD31-NPs under physiologically relevant
flow conditions and as a function of NP concentration. Previous studies have evaluated the
kinetics of NP association with surface immobilized target receptors via surface plasmon
resonance [69]; however, to my knowledge, quantitative studies evaluating the kinetics of NP
association with live cells have not been reported.
Using microfluidic flow chambers (shear of 2 dyne/cm2) and live cell imaging, I measured
the association of CD31-NPs to HUVEC monolayers over an NP concentration range of
10 to 100 µg/mL. CD31-NPs accumulated on the EC monolayer, whereas Control-NP at
100 µg/mL did not (Figure 1.2F). CD31-NP binding did not fully saturate the surface of the
cultured HUVECs over a 2-hour observation period even at the highest NP concentration
tested (100 µg/mL; Figure 1.2F and G). As predicted for first-order kinetics, the rate of
CD31-NP association scaled linearly with NP concentration (Figure 1.2H). Collectively,
these cell culture data demonstrate both that the CD31-NPs bind ECs with robust specificity
and that targeting is occurring under nonsaturating kinetics. This finding of nonsaturating
kinetics is consistent with previous examples of CD31 targeting to cultured ECs under flow,
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which showed apparent linear increases in NP accumulation with increasing NP dose, but a
direct comparison of my results with previous studies is difficult because the previous studies
did not directly examine the time dependence of NP accumulation [65, 66, 70]. The critical
point raised by the observation that targeting to ECs is a kinetic (time-dependent) process,
rather than equilibrium process, is that achieving robust accumulation within human kidneys
during a short period of ex vivo NMP will require the optimization of both NP concentration
and duration of exposure.
1.3 Delivering targeted nanoparticle kinetics ex vivo
To determine whether CD31-NPs can provide enhanced accumulation during ex vivo NMP,
eight experimentally viable human kidneys that had been declined for transplantation were
perfused with NPs. I first examined accumulation of CD31-NPs versus Control-NPs in
two separate kidneys using the same low NP dose (4 µg/mL). Note that this is the initial
NPconcentration in the perfusate reservoir; the actual concentration in the perfusate will
change as fluid moves in and out of the intravascular space during normal kidney function
and as NPs are depleted from the circulating perfusate. The goal of these experiments was to
establish the necessary methodology, including detection within tissue samples by quantita-
tive fluorescence microscopy. On the basis of the cell culture–targeting studies (Figure 1.2), I
predicted that several hours of perfusion would be necessary for substantial NP accumulation
at this dose. Therefore, using quantitative imaging of cryosections, I evaluated the accumula-
tion of either CD31-NPs or Control-NPs in glomerular vessels and surrounding interstitial
microvessels after 4 hours of NMP (Figure 1.3A and B). Although there was considerable
variability, CD31-NPs accumulated about 2.5-fold more than Control-NPs (93.2 ± 23.2
mm−2 (CD31-NPs) versus 36.8 ± 15.4 mm−2 (Control-NP) normalized mean intensity; ±
represents 95% confidence interval of the mean; Figure 1.3B).Notably, I did not find evidence
for extravascular accumulation of NPs in either CD31-NP or Control-NP perfused kidneys,
nor did I find NPs present in the urine during NMP. Accumulation within the vasculature
was heterogeneous. For both CD31-NP and Control-NP, there were vessels that showed NP
accumulation, whereas adjacent vessels appeared completely free of NP. Moreover, there was
a statistically significant elevation of accumulation in glomeruli compared to surrounding
interstitial microvasculature (p < 0.0001; Figure 1.3B).Accumulation within glomeruli was
notably heterogeneous with strong accumulation in discreet regions, whereas other vessel
segments appeared devoid of any accumulation (Figure 1.3A).
The cell culture results (Figure 1.2) suggested that accumulation of NP in renal vascular ECs
could increase over several hours. Quantification of CD31-NP association with glomerular
6 Delivering targeted nanoparticles during normothermic machine perfusion
Fig. 1.2 CD31 provides robust NP targeting in vitro. (A) Representative transmission elec-
tron microscopy image of poly(lactic acid)–poly(ethylene) glycol NPs. Scale bar, 200 nm.
(B) Quantification of NP size distribution and polydispersity index as measured by dynamic
light scattering for both 1’-dioctadecyl-3,3,3’,3’-tetramethylindocarbocyanine perchlorate
(DiI)– and 3,3’-dioctadecyloxacarbocyanine perchlorate (DiO)–loaded nanoparticles (NPs; n
= 3; a t test was used for statistical analysis). N.S., not statistically significant. (C) Represen-
tative 20× images of CD31-NPs versus Control-NPs after a 2-hour incubation with human
umbilical vein endothelial cells (HUVECs) in static culture. DiO-loaded NPs are shown in
green (right column) overlaid with brightfield images (left column). Scale bars, 150 µm. n =
3. (D) Representative fluorescence-activated cell sorting (FACS) histograms for HUVECs
treated identically to (C). (E) Quantification of triplicate FACS experiments as shown in (D).
n = 3. MFI, mean fluorescence intensity; a.u., arbitrary units. (F) Representative images of
accumulation of DiI NPs as a function of time on HUVECs in a microfluidic cell culture
during perfusion with CD31-NPs (100 µg/ml; top) or Control-NPs (100 µg/ml; bottom) at
2 dyne/cm2. Each image is 300 µm wide, representing the full width of the microfluidic
channel. NPs are pseudocolored green for better visualization. (G) Quantification of mean
area of positive fluorescence for flow experiments as performed in (F) at a range of concentra-
tions (n = 3 independent imaging regions for each dose and time point). Lines through data
represent fit to a rate equation. (H) Plot of rates as a function of NP concentration as extracted
from quantification in (G). Line through data represents linear fit. Rates are normalized to a
concentration of 10 µg/ml (dashed line, 1). All error bars represent 1 SD.
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ECs at early time points showed low NP signal that increased linearly with time (Figure
1.3C). In contrast, the NP signal observed in the kidney treated with Control-NPs appeared to
show a rapid accumulation to a low, saturated value within the first 30 min. The rapidity of
these nonspecific interactions, combined with their heterogeneous distribution throughout the
vasculature, suggested that these NPs may be accumulating at specific sites due to discrete
anatomical features of the tissue rather than binding to ECs. This raised the possibility
that the difference observed between CD31-NPs and Control-NPs could have resulted from
differences between the two kidneys rather than the nature of the NPs. Thus, although
these results are consistent with an enhancement of accumulation of CD31-NP relative to
Control-NP after 4 hours of perfusion, I next developed an approach to compare specific
versus nonspecific accumulation simultaneously in the same kidney.
To determine the extent of specific versus nonspecific NP accumulation within an individual
organ, I used a two-color NP approach where red-labeled (DiI dye) CD31-NPs and green-
labeled (DiO dye) Control-NPs were simultaneously administered to each perfused organ;
relative accumulation was then determined by quantifying the ratio of the two NP signals. The
two-color NPs were matched for intensity under identical imaging and analysis conditions,
as used for perfused kidney sections. The Control-NPs were specifically chosen for the green
DiO channel to ensure that any tissue autofluorescence (which is predominately present in
the green channel) did not artificially inflate the calculated degree of targeting specificity.
The analysis of Kidney 1 confirmed that CD31-NP targeting of renal ECs during NMP
is time-dependent. Because the in vitro studies showed that increasing NP concentration
increased the rate of delivery to ECs, I next focused on optimizing the concentration of
NPs in the perfusate fluid above the initial concentration tested (4 µg/mL). A mixture of
red CD31-NP (DiI) and green Control-NP (DiO) were administered to three donor kidneys,
each at matched doses of 10, 50, and 100 µg/ml. Individual images of either glomeruli
(masked to exclude any surrounding microvessels) or interstitial microvasculature (masked to
exclude any glomerular vessels if present) taken within cryosections cut from wedge biopsies
collected at various time points after perfusion were evaluated by quantitative microscopy.
On the basis of the presence of apparent nonspecific accumulation in the single-color Control-
NP kidney, I hypothesized that such areas would accumulate roughly equal amounts of red
(CD31-NP) and green (Control-NP). A salient feature observed in all human kidneys treated
with two color NPs were distinct regions of specific (red only) versus nonspecific (yellow,
about equal amounts of red and green) accumulation (Figure 1.4A-C). Quantitative evaluation
of yellow regions, either by line scan or total region evaluation, confirmed the nonspecific
(about 1:1) nature of NP accumulation in these regions (Figure 1.4D and E). Within the same
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Fig. 1.3 CD31 targeting enhances NP accumulation in perfused human kidney. (A) Rep-
resentative 20× fluorescent images of glomeruli (top) and interstitial microvessels (bottom)
for kidneys perfused with either CD31-NPs (left) or Control-NPs (right). Overlay images
show vascular stain (Ulex; green), DAPI nuclear stain (blue), and NP accumulation (red).
Scale bars, 100 µm. Images are cropped to provide finer details. (B) Quantification of indi-
vidual image MFI after background subtraction. Each image was normalized to the area of
Ulex vascular stain, and every dot represents an individual normalized image mean intensity.
The red dots correspond to the images shown in (A). *p < 0.0001 using a Mann-Whitney t
test. For the single CD31-NP-treated kidney, n = 35 for images of glomeruli and n = 59 for
images of microvasculature; for the single Control-NP–treated kidney, n = 31 for images of
glomeruli and n = 56 for images of microvasculature. (C) Time-dependent normalized mean
intensity values for CD31-NP versus Control-NP in glomeruli with corresponding fits to a
linear equation (CD31-NP, black line) or saturating kinetic equation (Control-NP, dashed
gray line). Error bars refer to 95% confidence window of the mean.
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field of view as these nonspecific regions, there were other regions with distinctly higher
CD31-NP-specific accumulation (about five-to-seven fold enhancement of CD31-NP relative
to Control-NP in the highlighted regions shown in Figure 1.4). The presence of regions
of about 1:1 CD31-NP/Control-NP accumulation in the same field of view and within the
same cryosection as other vessels with five-to-seven fold higher values of CD31-NP-specific
accumulation further validated the quantitative microscopy-based approach and supports
the conclusion that CD31-NPs are capable of enhancing retention in regions of the kidney
vasculature that do not otherwise accumulate NPs. In contrast, other regions of the same
kidney accumulate NPs by a different mechanism that is not improved by targeting. In both
cases, NP accumulation was exclusively intravascular.
The second round of experiments both validated the two-color NP targeting approach and
identified optimal experimental conditions for quantitative microscopy. However, the varia-
tions in NP concentrations administered to the kidneys analyzed in the previous three organs
limited the ability to directly assess how the benefits of CD31 targeting may vary from kidney
to kidney. In particular, I was not able to assess how the quality of a given organ might affect
specific versus nonspecific NP accumulation. Three additional donor kidneys (Kidneys 6 to
8) were perfused with 50 µg/ml each of CD31-NP (DiI-red) and Control-NP (DiO-green)
under identical perfusion and sampling conditions. High-resolution (40×) image analysis
was performed on cryosections taken from wedge biopsies collected before NP introduction
and at 2, 4, and 6 hours after NP administration. The perfusion period was extended to a
total of 8.5 hours for each kidney to provide a longer period for assessment of viability. The
histological analysis of these kidneys did not identify major differences among the three
organs, although the macroscopic appearances of Kidneys 6 and 7 were notably better than
that of Kidney 8 (Table 1.1). Kidney 8 also demonstrated a decline in urine production after
4 hours, further suggesting that the quality of this kidney was not as high as Kidneys 6 and 7.
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Fig. 1.4 Specific versus nonspecific NP accumulation. Representative thresholded 20×
fluorescent images of (A) glomeruli from the NP kidney (10 µg/ml), (B) interstitial microves-
sels from the NP kidney (50 µg/ml), and (C) glomeruli and interstitial microvessels from the
NP kidney (100 µg/ml) with white boxed regions highlighting areas of either specific or non-
specific accumulation within the same field of view or same section (DAPI, blue; CD31-NPs,
red; Control-NPs, green; NP overlay, yellow; Ulex, white). The boxed regions are shown
at a larger scale in the insets for both (A) and (B). The white dashed lines across the insets
in (A) refer to the line scale analysis shown in (D) for nonspecific (region 1) and specific
(region 2) accumulation. Scale bars, 50 µm. (D) Line scan plot of highlighted regions of
NP glomerular accumulation in (A) showing similar amounts of accumulation in nonspecific
regions with many more CD31-NPs relative to Control-NPs in more specific regions. (E)
Region quantifications depicting the total relative NPs signal (CD31-NPs/Control-NPs) for
the individual highlighted regions in (A) to (C); each bar represents the quantification of the
single image shown for the respective panel.
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The two kidneys with the best macroscopic appearance (Kidneys 6 and 7) also had the
highest average enhancement of CD31-NP accumulation relative to Control-NP in both
glomeruli and interstitial microvessels at 2, 4, and 6 hours of NP perfusion (Figure 1.5A and
B). Although there were individual glomeruli and regions of microvessels within these two
kidneys, where the accumulation was largely nonspecific, there were multiple glomeruli and
areas of interstitial microvessels where the CD31-NP accumulated at values about 5 to 10
times more that of the Control-NP (Figure 1.5A-C); one condition (Kidney 7 at 4 hours)
had a few regions where targeting benefit exceeded 20 times. In contrast, Kidney 8 had
generally reduced NP-targeting benefit that appeared to grow progressively worse over the
course of 6 hours, concomitant with the decline in urine production (Figure 1.5A-C). These
results further demonstrate that CD31-NPs are capable of accumulating via both specific and
nonspecific means and that the degree of CD31-specific accumulation varies significantly
among organs and in a manner that appears to correlate with the condition of the organ.
1.4 Nonspecific nanoparticle accumulation ex vivo
Confocal imaging revealed that nonspecific NP accumulation within the interstitial mi-
crovessels occurred primarily within the lumen of vessels, suggesting that this nonspecific
accumulation was not occurring because of engulfment by extravascular, tissue-resident
phagocytic cells (Figure 1.6A). Moreover, nonspecific NP accumulation localized to intravas-
cular regions that contained RBC-shaped structures stained by Ulex Europaeus Agglutinin
1 (Ulex; which stains RBCs in addition to ECs; Figure 1.6B). This feature suggests that
RBC-enriched vascular plugs may act as a sieve to accumulate high amounts of NPs in a
nonspecific manner. Quantitative imaging of nonspecific regions that co-localized with high
density RBC obstructions labeled by glycophorin A staining confirmed the nonspecific nature
of this mode of accumulation (Figure 1.6, C and D).
To better understand the basis of nonspecific sites of NP accumulation, I evaluated formalin-
fixed, paraffin-embedded sections of selective kidney biopsies. Hematoxylin and eosin
staining of samples of Kidney 8, which had substantial nonspecific accumulation of NPs in
interstitial microvessels (Figure 1.5A), revealed that there were extensive areas of vascular
plugging by RBCs and RBC fragments that were present before NP introduction (Figure
1.6D). Widespread vessel plugging in the cortex and medulla persisted throughout the 4 hours
of perfusion and was correlated with visual indicators of poor kidney perfusion (Figure 1.6D).
These plugs did not appear to be classical thrombi because they showed minimal amounts of
overt fibrin. The lack of fibrin is not unexpected, given that the perfusate consists of washed
RBCs and lacks fibrinogen, but I cannot rule out the possibility that fibrin microthrombi
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Fig. 1.5 Effects of CD31-NP targeting in perfused human kidneys. Quantification of
relative NP signal (CD31-NPs/Control-NPs) at 4 hours (h) for kidneys 6 to 8. Each point
represents an individual image of either interstitial microvessels (A) or glomeruli (B); non-
specific (1:1) accumulation is represented by dashed gray line. **p < 0.0001 and *p =
0.0024 according to a Wilcoxon signed-rank test. Colored data points correspond to the
quantification of the higher (red) or lower (green) specificity images shown in (C). (C)
Representative images of either higher or lower specificity regions of NP accumulation
in interstitial microvessels of kidney 6 (left) or glomeruli of kidney 7 (middle) and lower
specificity regions in glomeruli of kidney 8 (right; DAPI, blue; CD31-NPs, red; Control-NPs,
green; NP overlay, yellow; Ulex, white). Scale bars, 50 µm.
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were present downstream and caused an RBC- and NP-rich plug to back up behind the
obstruction. Alternatively, these plugs could represent vascular constrictions despite the
presence of a vasodilator in the perfusion solution. Similar vascular plugs were observed to
varying degrees in all kidneys in both glomeruli and interstitial microvessels; however, there
was substantial variability in the degree of obstruction present between biopsies sampled
at different time points and in different regional locations. This heterogeneity limits the
ability to draw a quantitative correlation between vascular obstruction and nonspecific NP
accumulation. Overall, gross evidence of poor perfusion provided a better correlation with
nonspecific NP labeling.
Discussion
Although molecular targeting of drug carriers is often referred to as “active” targeting [71],
molecular interaction forces (hydrogen bonds, electrostatic interactions) cannot provide a
physical force that actively pulls the conjugate to a site of disease because these forces only
operate over very small distances (< 0.5 nm) [46]. Thus, molecular targeting to a cell actually
works by enhancing the likelihood that a targeted NP will be retained by a target cell with
which it happens to come in contact. The maximal benefit from the addition of targeting
ligands to NPs requires optimization of the route of administration to ensure that the NPs
come in direct contact with the target cell of interest. For intravascular administration, ECs
represent an ideal target cell type because NPs do not need to escape from the vasculature to
reach them.
Many groups, including our own, have published on the advantages of therapeutic treatment
during ex vivo perfusion [30, 31, 72, 73]. However, this study was the first of its kind to
deliver cell-type specific targeted nanoparticles to human organs during NMP [74]. NMP
provides an opportunity to isolate the targeted organ and thereby ensure that the delivered
NPs only come in direct contact with the endothelium of interest. NMP also circumvents
competition with phagocytic cells of the liver and spleen, which tend to substantially dilute
any benefit associated with in vivo administration of molecularly targeted NPs. In addition,
NMP is typically performed with a serum-free perfusate, which further alleviates issues
associated with masking of targeting ligands by a protein corona [61, 62]. In this regard, NMP
represents, in many ways, the ideal setting for realizing the maximal benefit of molecular
targeting.
Despite this idealized nature of the NMP setting, a marked reduction between the degree of
targeting benefit during in vitro cell culture (under either static or flow conditions) versus
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Fig. 1.6 NPs accumulate at sites of vascular obstruction. (A) Three-dimensional projec-
tion of a z-stack of confocal images of a vessel containing a high density of nonspecific NP
accumulation in its lumen (DAPI, blue; CD31-NPs, red; Control-NPs, green; NP overlay,
yellow; Ulex, white). Dashed white line represents the point of apparent obstruction, and
arrows highlight apparent red blood cells (RBCs). Scale bar, 10 µm. (B) Representative
image of nonspecific co-localization of NPs with sites of high-density RBC (glycophorin
A, white; nonspecific NP, yellow) presumably representing vascular obstruction. Scale bar,
10 µm. (C) Quantification of relative NP signal (CD31-NP/Control-NP) for image in (B).
(D) Representative hematoxylin and eosin–stained images of Kidney 8 (100 µg/ml) before
NP introduction (pre-NP) or after 4 hours of NP perfusion. RBC occlusions are stained red.
Scale bars, 100 µm.
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an intact human organ was observed. Using static in vitro cell culture assays, CD31-NPs
accumulated as much as 80-fold above that of Control-NPs. However, when delivered
to human kidneys by NMP, targeted CD31-NPs accumulated only about two-to-four fold
above the level of Control-NPs in the vasculature of the renal cortex when evaluated from a
global average perspective. This two-to-four fold enhancement may seem relatively poor in
comparison to previous results in in vivo animal models of CD31-NP targeting to vascular EC,
where benefits have been observed as high as 10-to-20 fold [75, 41]. However, our detailed
analysis suggests that this two-to-four fold enhancement results from taking an average across
both nonspecific and CD31-specific modes of accumulation. These differences demonstrate
the benefits of using a microscopy-based approach as an alternative or complement to whole-
tissue quantification that necessarily loses information regarding the spatial heterogeneity of
accumulation. Moreover, the presence of these discreet regions of about 1:1 NP signal in
both glomeruli and interstitial microvessels served as an internal validation of the quantitative
microscopy approach.
The relative abundance of the nonspecific accumulation appears to be coupled to the condition
of the organ such that regional poor perfusion leads to more significant nonspecific accu-
mulation. I postulate that in order to have effective targeted nanoparticle delivery, sufficient
microvascular perfusion must be established throughout the entirety of the organ.
Chapter 2
Identifying and treating microvascular
obstructions
In the previous chapter, I had shown that it is possible to deliver antibody-targeted polymeric
nanoparticle drug carriers (NPs) to renal vasculature in the context of human kidney NMP
[74]. I demonstrated that antibody-mediated targeting of CD31, a pan-endothelial surface
protein, could enhance NP retention in well perfused organs. However, I also identified that
NPs accumulate non-specifically at sites of microvascular plugging that arose to varying
degrees in each of the 8 human organs evaluated [74]. This phenomenon exacerbated the
heterogeneity of nanoparticle delivery throughout the organ and left many regions of the
organ untreated. In addition, these obstructions impaired microvascular perfusion, likely
leading to reduced oxygen and nutrient delivery in the plugged regions. The extent of
microvascular plugging appeared to correlate with gross assessment of the quality of organ
perfusion suggesting that removal of these plugs during NMP may improve organ viability.
In this chapter, I identify that these microvascular obstructions appear to arise as a result of
local-renal production of fibrin(ogen) during cold-storage. As the staining reagents cannot dis-
tinguish between fibrinogen and soluble fibrin, I refer to this as fibrin(ogen). This fibrin(ogen)
is rapidly released into the microvasculature upon restoration of normothermia/normoxia -
both ex vivo or in vivo - leading to the formation of rouleaux-like RBC aggregates that plug in
the renal microvasculature. Critically, the rate of fibrin(ogen) production during cold-storage
varied substantially between donors with evidence suggesting that higher-risk donors (e.g.
those >70 y/o) may be more susceptible to this pathology. I further demonstrated that ex
vivo administration of plasminogen and tissue plasminogen activator (tPA) effectively clears
these fibrin(ogen)-rich microvascular obstructions leading to more stable hemodynamics,
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increased urine production, reduced markers of kidney injury, and significantly improved
delivery of vascular-targeted nanoparticles.
These results highlight the utility of NMP as both an experimental tool to identify novel mech-
anisms of human organ injury and a clinical platform for therapeutic revitalization of marginal
organs. Furthermore, they suggest that addressing fibrinogen-mediated, microvascular-
plugging following reperfusion may enable better utilization of marginal organs from higher-
risk donors and serve as critical first step to potentiate subsequent therapeutic delivery during
NMP.
2.1 Microvascular obstructions arise during perfusion
In the previous chapter, I observed varying degrees of microvascular obstructions in each of 8
human kidneys subjected to NMP (Figure 2.1A) [74]. Upon histological examination, these
obstructions appeared morphologically distinct from microthrombi. To better guide selection
of therapeutic treatment for these obstructions, I first sought to identify their provenance.
Transmission electron microscopy (TEM) on cortical biopsies from human kidneys subjected
to NMP showed no evidence of either fibrin mesh or platelets as would be classically
associated with either pre-existing donor microthrombi or newly formed microthrombi
(Figure 2.1B). Instead, the obstructions appeared to be aggregates of red blood cells (RBCs)
in a rouleaux-like formation (i.e. with the appearance of stacked coins) [74, 76, 77]. In vitro,
RBC rouleaux formation is mediated by increased fibrinogen levels produced by the hepatic
acute phase protein response to IL-6 [78]. Immunofluorescence microscopy confirmed
high levels of fibrin(ogen) present within discrete regions of cortical microvasculature in
human kidneys with confirmed microvascular obstructions (Figure 2.1C). Control isotype
Ab staining verified the specificity of the immunofluorescence stain for fibrin(ogen) (Figure
2.2). I refer to this as ‘fibrin(ogen)’ in the context of immunofluorescence (or histochemical
stain) of the microvascular obstructions because the reagents commercially available are not
able to distinguish between fibrinogen protein and the thrombin-cleaved fibrinogen product
known as fibrin.
To more clearly visualize the fibrin(ogen) and RBCs simultaneously, a Martius scarlet blue
(MSB) trichrome stain was employed (Figure 2.1D). The MSB staining revealed dense
aggregates of apparent fibrin(ogen) (red) and RBCs (yellow) in both peritubular capillaries
and glomeruli. Collectively, these data suggest that fibrin(ogen) is integral to the observed
RBC aggregates.
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Fig. 2.1 Fibrin(ogen)-rich microvascular plugs are present after NMP. Representative
images from perfused human kidneys 30 min after the start of NMP show microvascular
obstructions in (A) H&E stained samples (white arrows) and (B) TEM images depicting
microvascular obstructions with a rouleaux-aggregation of RBCs (scale bar is 10 µm). (C)
Fluorescent staining depicts co-localization of fibrin(ogen) (red) with vasculature (white
Ulex stain). Nuclei are stained blue. (D) Martius scarlet blue (MSB) stained samples (red
- fibrin(ogen); yellow - RBC) in glomeruli (top) and microvessels (bottom). Scale bars
represent 100 µm unless noted.
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Fig. 2.2 Staining controls for fibrinogen immunofluorescence staining. Isotype and sec-
ondary controls for the immunofluorescent fibrin(ogen) staining demonstrate the staining
specificity. Scale bars represent 100 µm.
Though it is classically associated with staining of fibrin, the MSB stain cannot definitively
distinguish between fibrinogen, fibrin monomer or fully polymerized fibrin [79, 80]. However,
extensive in vitro studies from literature suggest that fibrinogen alone is sufficient to form
rouleaux RBC aggregates without the need for thrombin conversion of fibrinogen to fibrin [77,
76, 81]. Additionally, there was no evidence of thrombin activity in the perfusate following
NMP (Figure 2.3). This lack of thrombin activity was expected given that the perfusate is
derived from washed RBCs and therefore lacks clotting factors and platelets. Additionally,
the perfusate is heavily heparinized to prevent any trace conversion of prothrombin to
thrombin. Nevertheless, the possibility that some level of fibrinogen conversion to fibrin
may be occurring in the formation of these microvascular obstructions can not be ruled out.
Thus, for the remainder of this thesis, I will use ‘fibrin(ogen)’ to specifically refer to protein
found in the intravascular compartment during NMP (either circulating in the perfusate or
deposited within the obstructions) where the detection reagents cannot distinguish between
fibrinogen, soluble fibrin monomer or insoluble fibrin polymer.
2.2 Fibrinogen is released from tubular epithelia into vas-
culature upon perfusion
The NMP procedure is performed in isolated kidneys with a heavily heparinized, washed
RBC perfusate that lack serum proteins, including fibrinogen. In vivo, serum fibrinogen
is primarily produced by hepatocytes. Thus, I anticipated that the obstructions must have
2.2 Fibrinogen is released from tubular epithelia into vasculature upon perfusion 21
Fig. 2.3 Absence of thrombin activity in kidney perfusates. Thrombin activity levels were
measured in perfusates collected after 90 min NMP in 3 separate kidneys. Each kidney was
tested in technical triplicates. No thrombin activity was observed.
formed in the donor when hepatic fibrinogen was present and then been retained through
the organ recovery and cold-storage process. To distinguish if the obstructions were present
in the donor organ prior to NMP, I assessed repeat kidney biopsies taken from the same
donor organ prior to NMP (i.e. at the end point of cold-storage) and then again after 30 min
of NMP (Figure 2A). Surprisingly, I found that the fibrinogen stain was initially localized
within tubular epithelia during cold-storage; here I presume that this intracellular protein
is in its original uncleaved state. This epithelial stain was then lost after 30 min of NMP
and coincided with the appearance of intravascular fibrin(ogen) concentrated at sites of
microvascular obstruction (Figure 2.4A).
Consistent with this finding, there was no soluble fibrin(ogen) in the perfusate prior to NMP,
but soluble fibrin(ogen) became detectable as early as 15 min following commencement
of NMP (Figure 2.4A and B). Soluble fibrin(ogen) was also detected at high levels in the
urine produced during NMP (Figure 2.4C). As urine is not recirculated in the NMP system
and fibrinogen is not filtered by glomeruli, these results suggest that tubular epithelium
may secrete fibrinogen in both the apical and basolateral directions. Alternatively, there
is evidence that proteins present in urine can be scavenged and translocated back into the
microvasculature [82]. The levels of soluble fibrin(ogen) appear much higher in urine than in
the perfusate. However, levels detected in the perfusate do not include insoluble fibrin(ogen)
bound within the obstructions, preventing a direct comparison of the amount of fibrin(ogen)
secreted into the urine versus the microvasculature.
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Fig. 2.4 Normothermic reperfusion triggers intravascular accumulation of tubular cell-
derived fibrinogen. (A) Representative images during cold storage demonstrate positive
stain in tubular epithelia in both MSB (left; pink stain) and immunofluorescence (right;
fibrinogen/fibrin(ogen)–red; Ulex–white; DAPI–blue). A biopsy after 30 min of NMP
depicts the migration of the positive stain to the vasculature. (B) Fibrin(ogen) levels in
perfusate as measured by ELISA in technical triplicate for samples taken before and after
NMP. Stars indicate samples below limit of detection. (C) Urine fibrin(ogen) levels in control
kidneys measured in technical triplicate at 30 min of NMP. (D) Representative images from a
clinical cohort of kidneys during cold storage that demonstrate positive MSB stain in tubular
epithelia with MSB stain (top). A biopsy taken 30 min post-transplantation depicts the
migration of the positive stain to the vasculature (bottom). Scale bars represent 100 µm.
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To assess if this process of fibrinogen secretion would occur in a clinical setting, I evaluated
a randomly-selected cohort of 15 human kidneys before and after clinical transplantation.
These kidneys were part of the control arm of an ongoing, randomized controlled trial in the
UK comparing the efficacy of NMP versus standard cold-storage (ISRCTN15821205) [26].
The only inclusion criteria for these organs was the presence of both a pre-transplant (at the
end-point of cold-storage) and 30-min post-transplant biopsy. These 15 organs represent
the first 15 organs that met this criterion from the clinical trial. Thus, the kidneys in this
cohort varied in age and under-went variable periods of cold-storage time (Table 2.1). The
paired biopsies from before and after transplant were again evaluated by MSB stain as an
indicator of fibrinogen/fibrin(ogen) localization. Positive MSB stain was observed after
cold storage (i.e. prior to transplant) specifically in the tubular epithelium of 6 of the 15
kidneys (Figure 2.5). Similar to the findings during NMP, this epithelial stain was lost 30 min
post-transplant and coincided with the presence of positive intravascular stain co-localized
with microvascular obstructions (Figure 2.4D).
Table 2.1 Demographics of DCD kidneys transplanted from cold storage arm of NMP
trial. Demographics from transplanted DCD kidneys from the cold storage arm of the clinical
trial assessing the benefits of normothermic machine perfusion.
Age CIT (hh.mm) High levels of tubular staining
55 19.44 Y
47 11 N
37 19.33 N
58 10.24 N
73 14.55 Y
67 13.36 N
59 11.53 N
74 21.24 Y
48 4.2 N
49 11.04 N
53 12.18 N
64 18 Y
28 19.36 Y
47 12 N
54 20 Y
Collectively, these data suggest that the fibrin(ogen) observed within the microvascular plugs
during NMP is derived from the renal tubular epithelium. During cold-storage conditions, the
newly synthesized fibrinogen is apparently sequestered within the tubular epithelium, perhaps
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Fig. 2.5 Tubular staining during cold storage of transplanted kidneys. Images from a
cohort of transplanted kidneys with various levels of tubular epithelial staining during cold
storage.
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due to the lack of active secretion at low temperatures [83]. Restoration of normothermia -
either during NMP or after transplant - appears to initiate rapid secretion in a manner that can
allow for transport into the microvasculature. Notably, extrahepatic synthesis of fibrinogen
- including within mouse and human kidney - has been previously reported in response to
ischemic injury and local inflammation [84–87].
2.3 Lysis of microvascular obstructions with tPA and plas-
minogen treatment
Having identified that NMP can initiate release of tubular fibrinogen into the vascular lumen,
I next evaluated if an FDA-approved fibrinolytic therapy could clear the microvascular
obstructions during NMP. Tissue plasminogen activator (tPA) is a commonly-used fibrinolytic
that can degrade both fibrin thrombi and fibrinogen-rich RBC aggregates [88, 89]. tPA
and similar thrombolytic agents have been previously evaluated in a pre-transplant setting
with mixed results [90–92]. However, these studies typically applied tPA in the absence
of its cofactor plasminogen; tPA catalyzes the conversion of plasminogen to the active
enzyme plasmin [92, 90]. As the perfusate lacks serum proteins - and therefore contains no
plasminogen - I hypothesized that exogenous plasminogen would be required for full effect.
To evaluate this hypothesis, a series of 6 human kidneys (i.e. each from different donors),
declined for transplantation were evaluated in 2 treatment groups during NMP: combined tPA
+ plasminogen (Kidneys 1-3) or tPA only (Kidneys 4-6). The two groups were randomized
for treatment versus control for 6 sequential donor organs received for research. Donor
demographics (age, cold-storage time and reason for transplant-decline) are provided as a
table in Table 2.2. Each organ underwent a standard clinical course of NMP with repeat
biopsies collected at 3 time points: (1) at the end of cold-storage prior to NMP to confirm
fibrinogen presence in tubular epithelia; (2) after 30 min of NMP to allow translocation in to
the vasculature; and (3) after an additional 60 min of NMP either in the presence of tPA +
plasminogen, tPA alone, or no treatment.
Five of the six organs displayed clearly positive MSB stain of the tubular epithelia in
the cold-storage biopsy prior to NMP (Figure 2.6A; Figure 2.7). However, all 6 organs
displayed measurable levels of microvascular obstructions following the initial 30 min of
NMP (Figure 2.6A). A custom machine-learning algorithm was used to quantify the %
area of microvascular obstruction identified by the MSB stain in a series of images from
each biopsy (Figures 2.8, 2.9, and 2.10). While levels of microvascular obstructions were
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Table 2.2 Human discard kidney donor demographics. Demographics from kidneys
included in the study are presented below.
Kidney ID Age (yrs) CIT (hr) Reason for decline Donor type Treatment
Kidney 1 65 28 high biopsy score DCD tPA-PLG
Kidney 2 75 24 infarcts DBD tPA-PLG
Kidney 3 65 22 anatomy DBD tPA-PLG
Kidney 4 51 36 damaged vein DBD tPA
Kidney 5 61 29 long CIT DCD tPA
Kidney 6 64 25 suspected malignancy DBD tPA
Kidney 7 49 12 poor function DBD CS
Kidney 8 39 12 high biopsy score DCD CS
Kidney 9 70 6 high KDPI DBD CS
Kidney 10 70 6 high KDPI DBD CS
Kidney 11 74 12 poor function DCD CS
Kidney 12 52 12 suspected malignancy DBD CS
Pair 1L 75 28 suspected malignancy DCD tPA-PLG
Pair 1R 75 28 suspected malignancy DCD PLG
Pair 2R 63 28 high biopsy score DBD tPA-PLG
Pair 2L 63 28 high biopsy score DBD PLG
Pair 3L 77 34 pt refusal DCD tPA-PLG
Pair 3R 77 34 pt refusal DCD PLG
Pair 4R 76 30 lesions found on lymph nodes DBD NMP
Pair 4L 76 30 lesions found on lymph nodes DBD tPA-PLG
Pair 5L 53 36 SSC found on lung DBD NMP
Pair 5R 53 36 SSC found on lung DBD tPA-PLG
Pair 6R 76 30 ATN DBD NMP
Pair 6L 76 30 ATN DBD tPA-PLG
variable prior to treatment, one hour of treatment with tPA + plasminogen completely cleared
microvascular obstructions in all 3 kidneys regardless of the initial degree of microvascular
obstructions present (* p < 0.0001; Figure 2.6A and B). Administration of tPA alone did not
clear the microvascular obstructions (Figure 2.6A and B) and actually displayed increased
levels of microvascular obstructions in 2 of the 3 organs evaluated.
An experienced renal pathologist blindly assessed a series of slides to validate the results
of the digital analysis across a random sample of organs (Table 2.3). The pathologist I
worked with defined any kidney with microvascular obstruction in glomeruli or peritubular
capillaries >50% to be unsuitable for transplant. This analysis was consistent with the quanti-
tative microscopy approach and confirmed the efficacy of the combined tPA + plasminogen
treatment.
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Fig. 2.6 Combined tPA + plasminogen treatment lyses microvascular obstructions. (A)
Representative images and microvascular obstruction quantifications (B) are shown from
single kidneys treated with tPA + Plasminogen or tPA only (* p < 0.0001, ** p < 0.05;
Mann-Whitney t-test). Scale bars represent 100 µm. (C) Resistance time traces as measured
during NMP for tPA + Plasminogen treated kidneys versus tPA only controls. Data points
represent the mean of all 3 kidneys evaluated in each group. Error bars represent standard
error of the mean. Arrow denotes point of tPA administration. (D) Total urine output was
measured after 90 minutes of NMP (* p = 0.0340; unpaired t-tests). Data points represent
individual kidneys.
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Fig. 2.7 Tubular staining during cold storage of transplant discarded kidneys. Images
from a cohort of transplanted kidneys that display various levels of tubular epithelial staining
during cold storage.
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Fig. 2.8 Demonstration of digital pathology approach to quantify color features follow-
ing MSB histochemical stain. (A) Representative images from different fields of view
collected from the same individual section of a human kidney biopsy. Images show average,
high, and low microvascular obstructions areas demonstrating the inherent variability of the
samples (top and bottom enlarged panels). The machine-learning based digital pathology
approach identifies the specific color associated with the feature of interest (middle panel
yellow stain). Scale bars represent 100 µm. (B) Representative distribution for quantification
of microvascular obstructions of 4x sections from a biopsy collected after 30 min of NMP.
This demonstrates the broad distribution and need for a robust method of quantification as I
have developed here. Red, yellow, and green data points refer to the corresponding images
from panel (A) of high, average and low areas of microvascular obstruction respectively.
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Fig. 2.9 Demonstration that digital pathology approach provides robust quantification
of microvascular obstructions (single donor organ). Representative images depict robust-
ness of the custom MATLAB code to isolate microvascular obstructions across a series of
images from a single donor. Samples, all stained with Martius scarlet blue, are able to distin-
guish areas of collagen (blue), fibrin(ogen) (red), red blood cells (yellow), and microvascular
obstructions where red blood cells and fibrin(ogen) overlap (left). The highlighted area of
fibrin(ogen) is identified, exported as a mask (middle) and overlaid on the original image to
ensure all positive areas are quantified (right).
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Fig. 2.10 Demonstration that digital pathology approach provides robust quantifica-
tion of microvascular obstructions (across multiple donors). A key challenge of digital
pathology is the variation of color schemes between different sample preparations. This
variability is demonstrated here between different donor samples which have different hues
of colors for the background (e.g. blue collagen) and features of interest (microvascular
obstructions). This approach circumvents the issue by using a machine learning approach
that is unique to each individual donor. Those allows for robust quantification across all
donor samples (middle and right columns).
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Table 2.3 Pathologist’s assessment of microvascular obstructions. Pathologist’s findings
from blinded biopsies are presented above.
Pathologist’s assessment Time point Treatment group
50–70% glomeruli have positive staining.
Majority are global. Few are segmental.
Focally positive areas of positive staining
in peritubular capillaries.
30 min NMP tPA + Plasmino-
gen
Peritubular capillaries and glomeruli are
completely negative.
90 min NMP tPA + Plasmino-
gen
Glomeruli are negative. Peritubular capil-
laries are negative. Noted different epithe-
lial staining.
Cold storage Plasminogen
More than 50% glomeruli are staining pos-
itively. Predominantly global. Focally pos-
itive areas of positive staining.
30 min NMP Plasminogen
80% of glomeruli are staining positively.
Predominantly global. Peritubular capil-
laries demonstrate more positive staining.
90 min NMP Plasminogen
Though the organs in this sequential series were not matched for demographic characteristics,
I nevertheless assessed indicators of physiologic function in the tPA + plasminogen group
relative to controls. Vascular resistance spiked to higher levels in the tPA only group between
30-60 min of NMP (Figure 2.6C). In contrast, the tPA + plasminogen group displayed
more stable resistance throughout NMP. While the tPA + plasminogen group appeared to
diverge from the controls prior to addition of tPA, it should be noted that plasminogen was in
circulation from time 0 and endogenous renal production of tPA has been previously reported
[93]. In addition to the more stable hemodynamics, the tPA + plasminogen group produced
significantly more urine than the tPA only group (Figure 2.6D). Collectively, these data
suggest that plasminogen is essential for efficacy of tPA and that this approach can effectively
clear microvascular obstructions during NMP.
2.4 Organ viability improves following treatment regimen
To more directly evaluate the effect of this treatment on organ viability, I evaluated 3
sequential pairs of transplant-declined organs recovered from 3 separate deceased donors
(Figure 2.11B). The use of paired organs from the same donor is intended to better control
for donor to donor variability for physiologic assessment. The three donors were aged 75
(Pair 1), 63 (Pair 2) and 77 (Pair 3) and were declined for suspected malignancy, biopsy
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score and patient refusal respectively (Table 2.2). Cold storage times ranged from 28 to 34
hours and the cohort included both DCD and DBD donors. The paired organs were randomly
assigned to receive either the combined tPA + plasminogen or plasminogen alone while
undergoing NMP. Plasminogen was chosen as the negative control in this series to evaluate if
the exogenous tPA was necessary or if endogenous tPA produced by the kidney was sufficient
for full therapeutic effect.
The organ pairs were perfused simultaneously on identical perfusion systems and repeat
biopsies were again collected at the same 3 time points: (1) at the end of cold-storage prior
to NMP to confirm fibrinogen presence in tubular epithelia; (2) after 30 min of NMP to allow
release in to the vasculature; and (3) after an additional 60 min of NMP either in the presence
of tPA + plasminogen or plasminogen alone. Quantification of the microvascular obstructions
revealed donor-to-donor variation in the initial levels of obstructions with Pairs 1 and 3 (75
y/o DCD and 77 y/o DCD) showing significantly higher initial values compared to Pair 2 (63
y/o DBD). Regardless of the initial level of obstruction, the combined tPA + plasminogen
treatment completely eliminated all microvascular obstruction by the 90 min time point (from
start of NMP) of the final biopsy (Figure 2.11A and B). By contrast, plasminogen alone
led to only a minor reduction in Pairs 1 and 3 with high levels of microvascular obstruction
remaining in all organs at the end of the NMP course.
To further confirm the results obtained via quantitative microscopy, levels of active plasmin
(i.e. the activated enzyme) and fibrin(ogen) degradation products in the perfusates were
evaluated. As expected, plasmin levels significantly increased in the kidneys treated with
combined tPA + plasminogen (* p < 0.01; Figure 2.12A). Similarly, fibrin(ogen) degradation
products (FDPs) also increased significantly after administration of combined tPA + plas-
minogen (* p < 0.01; Figure 2.12B). Modest effects were observed in the plasminogen only
control likely reflecting endogenous production of tPA by renal endothelium as suggested in
the prior series. Nevertheless, only the exogenous tPA + plasminogen treatment provided
rapid and complete fibrin(ogen) cleavage (Figure 2.11B).
Next, parameters of physiologic function and organ injury in the treated organs relative to the
paired controls were assessed. Treated organs demonstrated more stable vascular resistance
as compared to non-treated organs which had a characteristic spike in resistance between
30-60 minutes (Figure 2.11C). The volume of urine production was also numerically higher
in the treated organs by an average of 2.3 ±0.6-fold, though this did not reach statistical
significance with only 3 pairs of kidneys due to the relatively large variance between donors
(Figure 2.11D). Urinary NGAL, a marker of acute kidney injury was significantly reduced in
the treated kidneys compared to the paired controls (Figure 2.11E).
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Fig. 2.11 Assessment of paired donor organs suggests tPA + plasminogen improves
organ viability.(A) Representative images and microvascular obstruction quantifications (B)
are shown from paired kidneys treated with tPA + Plasminogen or Plasminogen only (* p <
0.0001, ** p < 0.05; Mann-Whitney t-test). Scale bars represent 100 µm. (C) Resistance
time traces as measured during NMP for Plasminogen only versus tPA + Plasminogen. Data
points represent the mean of all kidneys evaluated. Error bars represent standard error of
the mean. Arrow denotes point of tPA administration. (D) Total urine output was measured
after 90 minutes of NMP (* p = 0.1582; paired t-test). (E) Urine NGAL ratios of tPA +
Plasminogen to Plasminogen only controls for Pairs 1-3 before and after treatment (* p <
0.00001, ** p = 0.018754; multiple t-tests). (F) ICAM1 (* p < 0.001; multiple t-tests) and
(G) IL-6 levels from tissue lysates (* p < 0.00001; multiple t-tests) in Pairs 1-3. Samples
were processed in triplicate.
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Fig. 2.12 Biochemical assessment of paired kidneys after tPA and plasminogen treat-
ment. (A) Fibrin(ogen) degradation product levels (multiple t-tests; * p < 0.05 and (B)
plasmin levels (multiple t-tests; * p < 0.00001) are presented throughout the course of 90
minutes of NMP from Pairs 1-3.
Finally, changes in protein levels of soluble ICAM1 and IL-6 were measured from pre (i.e.
at end of cold-storage) to post NMP. Soluble ICAM1 - an enzymatically cleaved version of
the cell-surface adhesion molecule, present in a wide variety of pathological states - was
reduced by significant levels in the tPA + plasminogen group compared to plasminogen only
controls (Figure 2.11F) [94–97]. Similarly, levels of IL-6 - a rapidly produced mediator of
inflammation in renal IRI - rose in the perfusate to markedly higher levels in control organs
compared to the combined tPA + plasminogen group (Figure 2.11G) [98, 99]. Collectively,
these data confirm the effectiveness of using tPA + plasminogen to clear microvascular plugs
and suggest that doing so leads to improvements in organ viability.
2.5 Tubular epithelia produce fibrinogen in response to cold
time
The donor organs from the clinical series evaluated above displayed positive MSB stain in
6/15 kidneys (40%) prior to transplant. This ratio rose to 11/12 kidneys (92%) with positive
MSB stain in cold storage for the series of non-transplanted research organs with 12/12
demonstrating microvascular plugging post NMP. Notably, the cold-storage times of the 6
MSB positive kidneys in the clinical cohort was significantly longer than that of the MSB
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negative organs (Figure 2.13). The cold-storage times of the transplant-declined research
organs were even longer suggesting that this may be a determining factor in renal fibrinogen
levels. Hypothermic preservation of kidney allografts is thought to largely suppress protein
translation [100, 101]. However, based on this evidence, I hypothesized that fibrinogen levels
may be changing during cold storage.
Fig. 2.13 Cold storage times Cold storage times are presented for clinical and research
kidneys with fibrinogen negative or positive staining in tubular epithelium (* p = 0.0015;
unpaired t-test).
To test this hypothesis, repeat tissue biopsies were collected from a 52 y/o DBD donor
(Kidney 7) organ at 24 and 48 hrs of cold storage time and evaluated by western blot for
the fibrinogen gamma subunit (52 kDal). An increase in fibrinogen levels was observed at
48 compared to 24 hours (Figure 2.14A). To investigate this in further detail, a series of
five transplant-declined human organs were obtained early in cold storage (6-12 hours) and
subsequently stored for prolonged cold periods with repeat sampling of biopsies collected
out to 72 hours. Two organs from younger donors (Kidney 8 from a 49 y/o DBD and Kidney
9 from a 39 y/o DCD) were negative for MSB stain at the earliest time of 12 hrs. However,
the MSB staining showed a clear time-dependent increase in tubular staining out to 72 hours
(Figure 2.14B). A fibrinogen-specific ELISA performed on tissue lysates also demonstrated
a linear increase of fibrinogen levels during this period consistent with the MSB staining
(Figure 2.14C).
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Fig. 2.14 Tubular epithelia produce fibrinogen during cold storage at variable rates
depending on the donor.(A) Fibrinogen western blot and alpha-Tubulin loading controls
from Kidney 7. (B) Representative images of sections taken from repeat biopsy of a 49 y/o
DBD, 39 y/o DCD, and 74 y/o DCD kidney over the course of 72 hr. MSB stain shows
increasing fibrinogen accumulation in tubular epithelia during cold-storage (red). Scale bar
represents 100 µm. (C) Fibrinogen ELISAs performed on tissue lysates from repeat biopsies
in 5 kidneys from 4 separate donors taken over the course of 72 hr (left - younger donors;
right - older donors). Lines represent a fit to the linear phase of fibrinogen production. (D)
Rate of fibrinogen production for each organ as derived from fits in (C). Error bars refer to
SD. All measurements were taken in technical triplicate.
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In the older donors (Kidney 10 and 11 from the same 70 y/o DBD; Kidney 12 from a 74
y/o DCD), an initial linear phase of fibrinogen increase was observed within the first 24-30
hours, followed by a subsequent period of decay perhaps due to some type of enzymatic
degradation subsequent to cell death (Figure 2.14B and C). The organs from the older donors
had significantly faster rates of fibrinogen increase compared to the younger donors (Figure
2.14D). Within 24-30 hours, the organs from older donors reached levels that took 72 hours
to achieve in the organs from the younger donors. Notably, older donors are known to be
more susceptible to damage from cold-storage preservation [102].
2.6 Improved specificity of targeted nanoparticles follow-
ing treatment
The process of RBC plugging during NMP was initially discovered due to the non-specific
accumulation of vascular-targeted nanoparticles (NPs) at the obstructed sites [74]. Therefore,
I hypothesized that vascular-targeted NPs given after tPA + plasminogen treatment on NMP
would show more selective targeting after restoration of microvascular perfusion. To evaluate
this, another series of 3 sequential pairs of non-transplanted donors organs were evaluated
(Pair 4 - 77 y/o DBD; Pair 5 - 53 y/o DBD; and Pair 6 - 76 y/o DBD). Based on the preceding
data, each organ was held to a minimum of 30 hours cold-storage time to ensure high levels
of fibrin(ogen) and subsequent microvascular plugging. Organs on NMP were either treated
with tPA + plasminogen or untreated to replicate the conditions of the prior study [74].
Similar to the two-prior series, the treated organs demonstrated improvements in stability of
hemodynamics (Figure 2.15A); urine production (Figure 2.15B) and reduced urinary NGAL
as a marker of renal injury (Figure 2.15C).
To evaluate the efficacy of vascular targeted nanoparticle (NP) delivery, I repeated the
previously published experimental design of co-administration of targeted and non-targeted
NPs during NMP with and without the tPA + plasminogen treatment. Here, otherwise
identical NPs were loaded with either red fluorescent dye and conjugated with an anti-ICAM2
antibody or loaded with a matched intensity of a green fluorescent dye and conjugated with a
non-binding matched isotype control. (I was unable to use the anti-CD31 antibody employed
in the prior study because the epitope recognized by this antibody appeared to be eliminated
by the tPA + plasminogen treatment; Figure 2.16.) The NP were co-administered in both
of the paired organs at 90 min after the initiation of NMP (to allow for the 60 min tPA
+ plasminogen treatment in the treated organ). Both paired organs were perfused for an
additional 4 hours and end point biopsies were collected to assess the specificity of NP
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Fig. 2.15 Lysing vascular obstructions improves specificity of vascular-targeted
nanoparticles. (A) Variation in renal blood flow (RBF) with or without treatment (* p
= 0.0126; paired t-test). (B) Total urine production after one hour of NMP with or without
treatment (* p = 0.0157; paired t-test). (C) NGAL levels in urine after one hour with or
without treatment (* p = 0.0023; paired t-test). Red data points are from Pairs 4-6 that
were stored for prolonged cold times of 30-36 hrs to build high fibrinogen levels. Each data
point represents the outcome from a single kidney. (D) Representative images of glomeruli
(left) and microvessels (right) from paired kidneys receiving either tPA + plasminogen
treatment (treated) or NMP alone (untreated) prior to injection of combined ICAM2-NPs
and Isotype-NPs labeled with two separate fluors (ICAM2-NPs, red; Isotype-NPs, green;
NP-overlay, yellow; Ulex, white). Scale bars represent 100 µm. (E) Quantification of relative
NP signal (ICAM2-NPs/Isotype-NPs) at 4 hours of NP circulation. Each point represents an
individual image of either interstitial microvessels (top) or glomeruli (bottom); nonspecific
(1:1) accumulation is represented by a dashed line (* p < 0.0001; Wilcoxon signed-rank test).
Each data point represents an image taken from a section of a kidney.
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targeting via quantitative microscopy to evaluate relative accumulation of the red ICAM2 NP
and green Control-NP.
Fig. 2.16 tPA and plasminogen treatment lyses CD31 epitope (A) IHC staining of CD31
(10x) and ICAM2 (20x) images during cold storage, at 30 min of NMP and at 90 min of NMP
with or without tPA + plasminogen treatment. (B) Quantitative microscopy calculations of
fluorescent CD31 and ICAM2 staining during cold storage, at 30 min of NMP and at 90 min
of NMP with or without tPA + plasminogen treatment in microvessels and glomeruli.
In the absence of tPA + plasminogen treatment, there was no observed benefit of NP targeting.
ICAM2-NP and Control-NP accumulated at identical levels presumably via a sieving mecha-
nism at the site of vascular obstructions, as previously observed (Figure 2.15D and E) [74].
However, in the paired kidney the retention of the non-targeted Control-NP were significantly
diminished in the absence of the microvascular obstructions. The ICAM2-targeted NP were
retained in areas of both glomerular and peritubular capillary microvasculature. The quantita-
tive microscopy approach revealed ~3-fold retention benefit in the glomeruli (p < 0.0001)
and ~20-fold benefit in the microvessels (p < 0.0001) (Figure 2.15E). The targeting benefit
in glomeruli was similar to what was observed in well perfused kidneys in the previous
pervious chapter, while targeting to the microvessels improved ~10 fold from the initial study
[74]. These data suggest that clearance of microvascular obstructions is likely an essential
precursor for effective delivery of targeted nanomedicines to renal endothelium during NMP.
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Discussion
The basic principles for successful preservation of organs for transplant were established dur-
ing pioneering studies in the late 1960s through late 1980s [103–105]. These efforts defined
5 key physiologic modes of failure to be addressed during preservation: 1) Hypothermia-
induced cellular swelling due to impaired Na+ pump activity at cold temperatures; 2)
Ischemia-induced intracellular acidosis; 3) Tissue edema from imbalance of osmotic pres-
sures; 4) Reperfusion-induced production of reactive oxygen species; and 5) Depletion of
substrates for ATP regeneration following reperfusion. Based on these 5 pillars, preservation
fluids (e.g. University of Wisconsin solution) were designed to enable safe preservation of
deceased-donor kidneys for ~24 hr [103]. However, these principles of safe preservation
were established in an era with much less demand for organs and a donor population that
was generally healthier. The poorer outcomes associated with more marginal donor organs
prevalent today - even within the standard preservation cutoff times - suggests the possibility
that there may be additional as yet unidentified modes of failure that need to be addressed to
ensure these higher-risk organs can be safely preserved and transplanted.
The ability to perform preclinical research on the same non-transplanted organs that the
community looks to revitalize provides a unique opportunity to identify these additional
failure modes. This discovery process is further aided by the capacity of NMP to simulate in
vivo-like conditions in a controlled ex vivo setting. The phenomenon uncovered in this study
was identified as a direct result of the fact that ex vivo NMP can mimic how higher risk organs
would behave in vivo post-transplant. The isolated setting of NMP further allowed me to
identify renal tubular epithelium as the source of fibrinogen by eliminating the confounding
source of hepatic fibrinogen. Thus, in the context of pre-clinical research, the approach
employed here can enable discovery of new mechanisms of human pathophysiology that are
intrinsic to a given organ type.
Regarding the specific mechanisms driving microvascular obstructions during NMP, the data
suggest that factors produced within the kidney are sufficient to elicit these lesions. The fact
that the obstructions are densely positive for fibrin(ogen) further suggests that the observed
time-dependent increase in fibrinogen levels during cold-storage is central to this process.
Nevertheless, the data do not conclusively demonstrate that renal fibrinogen is sufficient to
drive the obstructions in the absence of other co-factors. Von Willebrand Factor has also
been identified as a mediator of RBC-aggregation in the context of ischemia-reperfusion
injury [106, 107]. Von Willebrand Factor, like fibrin(ogen), is also sensitive to plasmin
degradation. Thus, there is a clear need for a future mechanistic investigation to complement
the translational focus of this work. A comprehensive identification of the upstream regulators
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of fibrinogen production and any other proteomic changes during cold storage may inform
alternative therapeutic strategies with greater specificity than plasmin. This more detailed
mechanistic study should also directly evaluate how hypothermic perfusion - a ubiquitous
method of preservation in the U.S. and Europe - influences the rate of fibrinogen production
and the formation of microvascular obstructions.
Though there may well be preferable alternatives to the therapeutic regimen developed
here, the utility of this approach lies in its capacity for immediate translation. tPA is an
FDA-approved therapeutic with a long history of use in the context of organ transplantation
[91, 108]. Plasminogen is currently awaiting FDA-approval as a replacement therapy for
patients with plasminogen-deficiency but has been shown in multiple clinical trials to be safe
for use in humans [109–113]. In the U.K., the well-established clinical use of NMP will
allow me to directly translate the regimen developed here within current clinical practice.
While NMP is not currently in clinical use in the U.S., intra-arterial drip of low-dose tPA
delivered ~10-15 min after transplant may be an effective strategy to achieve the same effect
of clearing microvascular plugs in marginal organs with high levels of fibrinogen. In either
case, the focus will be increasing utilization of the higher-risk organs that are currently being
discarded in high numbers while patients die on the waitlist every day.
Given the high degree of variability present in marginal human organs, it seems unlikely
that a one-size-fits-all approach will suffice for full pre-transplant revitalization. Indeed, I
believe that the repair of marginal organs pre-transplant will likely require a personalized
approach with therapies being adapted to the specific needs of a given organ. Within this
paradigm, modular drug delivery systems (e.g. nanoparticles) hold significant promise due
to their capacity to deliver a wide array of different therapeutic payloads including drugs,
gases, proteins, nucleic acids, and gene-editing agents [7, 114, 115]. However, even the most
well-suited therapies will not be effective if they can’t reach the intended site of action. I
propose that treating the microvascular obstructions identified here will be a critical first
step in any pre-transplant treatment regimen. First and foremost, this will ensure adequate
restoration of oxygen and nutrient delivery throughout the organ. However, these results
suggest this approach will further potentiate use of the full toolkit of potential therapeutic
options currently being explored for use during NMP. To begin building out a therapeutic
toolkit, I next sought out to identify a drug that would be appropriate to load into nanoparticles
and protect against renal ischemia-reperfusion injury.
Chapter 3
Delivering an NLRP3 inhibitor during
normothermic machine perfusion
Having established better microcirculation for the improved delivery of targeted nanoparticles,
I began to investigate different therapeutics that would be well suited to load into the targeted
nanoparticles. As morbidity among the donor population continues to rise, more marginal
kidneys, with high sensitivity to ischemia reperfusion injury (IRI), are being offered for
renal transplantation [6, 5]. As there are currently no pre-transplantation therapies that work
to minimize the effects ischemia reperfusion injury, thousands of these susceptible organs
are discarded annually [116]. I hypothesize that targeting IRI with therapeutics prior to
transplantation may be a viable strategy in increasing patient access to marginal organs.
Post-transplant IRI can result in acute kidney injury manifested as delayed graft function,
which may ultimately impact long term graft survival [5]. IRI is multifactorial a process
that is a result of the restoration of normoxic conditions following transplantation [6, 14].
A critical mechanism in IRI is the intracellular assembly and activation of the NLRP3
inflammasome, which triggers production of inflammatory caspases and the maturation of
the prototypic inflammatory cytokines IL-1β and IL-18 [17, 16]. Inhibition of the NLRP3
inflammasome has been proposed as a therapy to prevent IRI, but to date, relevant therapies
have been delivered entirely in in vivo animal models [17, 117, 18, 118]. Biodistribution
challenges, off-target effects, and the need for increased dosing are commonly associated
complications of in vivo drug delivery which ultimately hinder translation of a therapy to
bedside care [119]. Additionally, in order for NLRP3 inhibition to be effective in protecting
against IRI, the therapy must be delivered before transplant.
Emerging technologies, like renal ex vivo normothermic machine perfusion (NMP), have
allowed us to deliver therapeutics pre-transplantation in a clinically relevant setting. As
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previously discussed, NMP serves as a unique platform for the delivery of pre-transplant
therapies ex vivo [120, 74]. On an isolated circuit, therapies can be delivered directly to
the organ of interest without the usual challenges of systemic delivery (e.g. off-target drug
effects, systemic toxicity) [119]. Delivering NLRP3 inhibitors in this setting will allow us to
treat the organ, rather than the patient, prior to transplantation.
In this chapter I investigate MCC950, a selective NLRP3 hydrolysis inhibitor, to ameliorate
renal ischemia reperfusion injury [121]. In murine and human organ culture models of renal
IRI, I have shown that MCC950 has a protective effect. Additionally, I have demonstrated
that NMP provides a highly effective platform for the isolated delivery of pre-transplant
therapies. I propose that blockade of the NLRP3 inflammasome with MCC950 may be a
viable therapeutic strategy in the search for interventions that may improve early allograft
function. MCC950 may be an optimal drug to load into targeted nanoparticles for prolonged
delivery and protection against IRI and increase marginal organ utilization.
3.1 NLRP3 inhibition with MCC950 is protective against
renal ischemia reperfusion injury in mice
Activation and assembly of the NLRP3 inflammasome has been shown to be a key mechanism
in the regulation of renal IRI [17, 16]. To assess if inhibition of the inflammasome was
protective against IRI I applied a bilateral clamp model of renal IRI wild type (WT) and
NLRP3 knockout mice [122]. Using serum creatinine and blood urea nitrogen (BUN) as
clinically accepted markers for renal injury, NLRP3 knockout mice had lower levels of serum
creatinine and BUN than WT mice (Figure 3.1, A and B) [123]. Additionally, there were also
significantly reduced levels of tubular necrosis in the outer strip of the medulla, the portion
of the kidney most sensitive to ischemia reperfusion injury (Figure 3.1, C and D). Both WT
and NLRP3 knockout mice had similar basal levels of serum creatinine, BUN, and tubular
necrosis in sham conditions (Figure 3.1, A-D). Previous, similarly executed experiments
support these findings [122, 124].
Confirming that an NLRP3 knockout is protective against IRI, I next sought to test if a small
molecule inhibitor of NLRP3, delivered just prior to clamping, could produce the same
phenotype. I chose to investigate MCC950, a small hydrophobic drug, that has been shown to
act as a potent NLRP3 inhibitor by directly targeting the NLRP3 ATP-hydrolysis motif [121].
When MCC950 (7.5 mg/kg) was delivered systemically intravenously to mice subjected o
renal IRI, there was a significant reduction in both serum creatinine and BUN levels (Figure
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3.1, A and B). Historically, MCC950 has been delivered intravenously in mice at doses
between 3 and 10 mg/kg, suggesting that I am administering a dose within the correct range
to observe an effect [125, 126]. There was a significant reduction in levels of tubular necrosis
following MCC950 treatment (Figure 3.1, C and D). However, the same reduction in injury
markers that was seen in the full NLRP3 knockout model was not observed. I hypothesize
that the obstacles of effective systemic drug delivery (i.e. phagocyte-mediated elimination,
off-target effects) may have contributed to the incomplete attenuation of these injury markers
[29]. Having shown that NLRP3 inhibition with MCC950 has promise in reducing the effects
of IRI in vivo, but does not have a full protective effect, I next moved to deliver MCC950 to
human kidneys on an isolated ex vivo NMP circuit in an attempt to obviate the challenges of
in vivo drug delivery.
3.2 Organ culture models serve as a platform for dose titra-
tion studies
To identify the optimal dose of MCC950 for human organs ex vivo, models of organ culture
were utilized. Organ culture allows us to preserve tissue architecture and cellular interactions
that may not be possible in standard cell culture assays [127]. Additionally, this method
enables us to turn one whole organ into potentially thousands of replicates. In this study,
dissected tissue from 4 separate human kidneys was incubated in various concentrations of
MCC950 previously used in the literature (Table 1). Following the period of treatment, the
tissue was challenged with a period of hypoxia and then subjected to a model of reperfusion
(Figure 3.2A). Measuring levels of IL-1β and IL-18 in the reperfusate, IC50 curves were
constructed to determine the most appropriate concentration of MCC950 to deliver during
NMP. In human organ culture models of IRI, a full reduction of both IL-1β and 1L-18 was
noted at 100 µM of MCC950 and I chose to proceed with that concentration for NMP.
3.3 Normothermic machine perfusion of a kidney improves
with NLRP3 inhibition
Here, when MCC950 was delivered to a series of 4 single kidneys on the ex vivo circuit
(Table 3.1) there was improved total urine output and significantly higher renal blood flow
measurements when compared to controls (Figure 3.3, A and B). As it takes a certain amount
of time for the NLRP3 inflammasome to assemble, the organ was allowed to stabilize or 90
minutes prior to delivering MCC950. It is important to note that while these kidneys were
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Fig. 3.1 NLRP3 inflammasome inhibition protects murine kidneys from ischemia reper-
fusion injury. (A) Serum creatinine and (B) blood urea nitrogen (BUN) levels (*p < 0.0001,
**p = 0.0052, ***p = 0.0012; unpaired t-tests) are presented across all experimental groups
of mice. Single data points represent individual mice in a group (n = 4). (C) Representative
20x images of the outer strip of the medulla are presented across all groups. (D) Percent of
necrotic tubules were quantified in the outer strip of the medulla levels (*p < 0.0001, **p =
0.0197; unpaired t-tests).
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Fig. 3.2 NLRP3 inflammasome inhibition is possible during human kidney organ cul-
ture. (A) A schematic from the human organ culture experiments following static cold
storage is presented. MCC950 dose response curves during human organ culture are pre-
sented for (B) IL-1β and (C) IL-18. Error bars represent SEM.
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matched to be DBDs with long cold times, they did not come from the same donors, making
paired analysis inappropriate for these measures. While perfusion parameters have been
suggested to correlate with improved organ function, they have yet to be fully understood,
suggesting other markers of organ health and function should be considered [128, 49, 27].
Table 3.1 Donor demographics. Donor demographics are presented for all transplant
discarded human kidneys used in the presented experimental series.
Kidney ID Age CIT Reason for decline Treatment group
Kidney 1 73 14 high biopsy score CS
Kidney 2 46 27 retrieval damage CS
Kidney 3 63 17 no suitable recipient available CS
Kidney 4 71 30 poor artery anatomy CS
Kidney 5 76 33 age & long CIT NMP + MCC950
Kidney 6 35 33 long CIT NMP + MCC950
Kidney 7 68 27 suspected cancer NMP + MCC950
Kidney 8 68 27 suspected cancer NMP + MCC950
Kidney 9 63 26 suspected cancer NMP + saline
Kidney 10 76 30 suspected cancer NMP + saline
Kidney 11 53 36 suspected cancer NMP + saline
Kidney 12 76 30 ATN NMP + saline
Additionally, decreased levels of cytokine in the perfusate were observed after 4 hours of
MCC950 circulation when compared to controls (Figure 3.3C). Higher cytokine levels during
perfusion have been associated with higher levels of DGF post transplantation. Lower levels
of cytokine production associated with MCC950 administration suggest that the treatment
not only inhibits the NLRP3 inflammasome but in doing so better prepares the organ for
transplantation. To confirm this, one must look beyond this period of treatment to see how
the organ behaves longer term.
3.4 Human organ culture following normothermic machine
perfusion serves as a model for IRI post-transplant
To evaluate how the organ responds post-NMP, methods of human organ culture can be
utilized. Following treatment during NMP tissue can be dissected, challenged in a hypoxic
chamber, and allowed to reperfuse to simulate what the organ may experience following
an additional period of cold storage and transplantation (Figure 3.4A). Our preliminary
evidence suggests that even 8 hours after the initial dose of MCC950, tissue produced
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Fig. 3.3 MCC950 delivery during renal NMP improves perfusion parameters. (A) Urine
output are presented from control (NMP + saline) and treatment (NMP + MCC950) groups.
Each data point represents the output from an individual kidney. (B) Renal blood flow
parameters are presented from control and treatment groups (*p < 0.05, multiple t-tests).
(C) Perfusate cytokine levels are presented from control and treatment groups (*p < 0.05,
multiple t-tests).
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mostly undetectable levels of IL-1β (Figure 3.4B) and significantly less IL-18 (Figure 3.4C).
These results support that delivering MCC950 during NMP may be a viable pre-transplant
therapeutic strategy to protect marginal organs from IRI.
Fig. 3.4 Human organ culture supports MCC950 delivery during renal NMP is protec-
tive against IRI. (A) A schematic from the human organ culture experiments following
normothermic machine perfusion is presented. (B) IL-1β (*p = 0.0002, unpaired t-test) and
(C) IL-18 (*p = 0.0373, unpaired t-test) levels are presented from the reperfusion media
following a period of normothermic machine perfusion.
Discussion
Although ischemia reperfusion injury is largely regulated by the NLRP3 inflammasome,
this injurious process is known to be multifactorial and has yet to be completely understood
[6, 14, 17, 16, 129]. Due to the nature of IRI, it is unlikely that the inhibition of a single
pathway will fully ameliorate the long term effects of this process. To protect marginal organs
from IRI following transplant, a dynamic therapeutic toolkit must be built to address multiple
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mechanisms of injury and be adaptable to specific organ profiles. I chose to investigate
MCC950, a small hydrophobic drug, that has been shown to act as a potent canonical and non-
canonical NLRP3 inhibitor by directly targeting the NLRP3 ATP-hydrolysis motif [121, 126].
MCC950 has been studied in a variety of experimental models of inflammation and has been
shown to alleviate colitis, stroke, asthma, and even Parkinson’s disease [130–133]. Most
pertinently however, in models of porcine liver transplantation, MCC950 administration has
been shown to reduce IRI [134]. In this study, I demonstrated that delivering an NLRP3
inflammasome inhibitor ex vivo can protect marginal organs against IRI as one facet of a
potential therapeutic strategy.
Methods of human organ culture help us to better understand the therapeutic efficacy of a
treatment in question by allowing us to preserve tissue architecture and cellular responses
that may be lost in cell culture models [127]. Additionally, this approach enables high
throughput screenings of therapeutic agents and dosing by turning one human organ into
theoretically thousands of replicates. As transplant-discard human organs are an extremely
rare and valuable resource, it is important that transplant scientists continue to devise and
implement strategies that maximize the potential of these gifts. Once initial screenings have
been conducted and proper dosages have been determined in a human organ culture setting,
scientists can move to more clinically relevant models and treat whole organs using ex vivo
normothermic machine perfusion [26, 74].
As treatments are delivered to single organs on ex vivo perfusion circuits more frequently, it
will become imperative that there is an understanding of (1) the intra-organ biodistribution
of the drug administered and (2) whether or not there is a need to target these drugs to
specific cell types in order to make them more effective therapeutics in the short window
pre-transplantation [74, 30, 31, 24]. Targeting therapies has been shown to enhance the
retention of drugs, allowing for more rapid cellular internalization [48, 39]. MCC950 is a
small hydrophobic drug that, when delivered without a targeting ligand, will passively diffuse
through the cellular membranes of all accessible cells types within a kidney through random
drug-cell interactions [135]. As the NLRP3 inflammasome has only been shown to be active
in the cytosol of innate immune cells (e.g. macrophages, monocytes, and dendritic cells) and
some resident kidney cells (e.g. tubular epithelium and podocytes) it is likely that I delivered
MCC950 at a higher than necessary dose to see a protective effect against IRI [136]. In the
case that targeting MCC950 to multiple cell types is necessary for more effective treatment,
one possible strategy is to encapsulate the drug into a polymeric nanoparticle carrier.
Using nanoparticle technologies also enables us to deliver encapsulated drugs over a pro-
longed period of time [137]. Polymeric nanoparticles can be formulated to slowly release
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their contents over a period of hours, days, or even weeks as they degrade by hydrolysis
[56, 7]. Although there is no current consensus on how long IRI persists post-transplantation,
it has been shown that IRI in susceptible organs may result in acute kidney injury or graft
loss [5]. Delivering therapeutic agents over a sustained period of time post-transplantation
may help mitigate the deleterious effects of IRI. From this work, I propose that inhibition
of the NLRP3 inflammasome may be one approach to protecting marginal organs from IRI.
These pre-transplantation therapies may ultimately increase the rate at which these marginal
organs are utilized for transplantation.
Chapter 4
Whole organ viability assessments
As previously discussed, ex vivo organ perfusion has emerged as both a clinical and research
platform with the potential to improve safe utilization of marginal organs [138, 119, 139–
141]. In the clinical context, ex vivo organ perfusion provides an opportunity for more
detailed assessment of organ function to better stratify safe versus compromised donor
organs. Indeed, recent clinical experiences in kidney and other organs suggest that ex vivo
organ perfusion can improve utilization of organs that had been previously declined without
sacrificing outcome [120, 138, 142, 143]. Parallel efforts in pre-clinical research have been
exploring therapeutic strategies to potentially revitalize compromised organs to make them
safe for transplantation [119, 144, 30, 31, 37]. In either setting, sophisticated diagnostic tools
are essential to provide an objective and quantitative assessment of organs.
In the prior chapters, I have developed diagnostic imaging tools for quantitative assessment
of biopsy specimens to evaluate delivery of targeted nanomedicines and to quantify the
extent of microvascular obstruction during normothermic machine perfusion (NMP) of
transplant-declined human kidneys [74]. Though this approach is useful for this type of
higher-resolution detailed analysis, biopsy-based diagnostics have two key limitations: (1)
Invasive-nature of the assessments limits the ability to perform longitudinal measurements of
dynamic behavior; and (2) assessment is limited to the tissue within the biopsy and cannot
provide a global assessment of the organ.
In this chapter, I sought to develop a complementary diagnostic tool that could overcome the
limitations of biopsy-based assessments. I hypothesized that ex vivo tomography imaging
could enable non-invasive and whole-organ diagnostic assessments. I specifically focused
on evaluation of contrast-enhanced computed tomography (CT) as an assessment of organ
perfusion characteristics; my prior work suggests that establishing good microvascular
perfusion is a prerequisite for any subsequent therapeutic efforts at organ revitalization. In
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a series of pig and non-transplanted human kidneys, I first developed quantitative tools for
analysis of CT-image-stacks. I then utilized these tools for assessment of non-transplanted
human organs either before, during or after normothermic machine perfusion. These data
demonstrate the potential for ex vivo tomographic imaging as a preclinical research tool and
suggests contrast-enhanced CT could also have potential utility for organ assessment in a
clinical setting.
4.1 CT imaging to assess renal vasculature ex vivo
In the previous chapters, I have developed advanced quantitative microscopy tools to analyze
biopsies collected before, during and after normothermic perfusion. However, the destructive
nature of repeat biopsies limits the ability to perform dynamic assessments and restricts
analysis to the collected tissue, precluding whole-organ assessment. To overcome these
limitations, I sought to develop a complementary whole-organ tomography imaging method.
For this study, I specifically focused on contrast-enhanced computed tomography (CT) to
enable ex vivo quantification of organ perfusion (Figure 4.1A).
I first sought to develop a simple quantitative metric that could be used to parameterize the
quality of perfusion for robust statistical analysis. Porcine kidneys procured from a local
slaughterhouse were infused with cold crystalloid and a bolus of iohexol contrast reagent.
Three repeat axial scans were collected in quick succession to capture the initial dynamics
of contrast filling in the organ (Figure 4.1B). From these 3D image stacks, the volume of
contrast positive vasculature was calculated relative to the full volume of the organ measured
during that scan. The fraction of contrast positive volume scaled roughly linearly in time,
allowing a simple parameterization by fitting this trend to a line (Figure 4.1C).
The quantification of the initial dynamics of whole organ contrast filling provides a simple
metric for comparison. However, this global metric does not provide regional information
regarding the quality of microvascular perfusion in a given organ. To complement the volume
fraction measurement, I added a fourth scan collected at 5 min after the initial bolus of
iohexol was administered. This time point allows contrast to fully access microvascular
regions and enter the parenchyma providing a clear qualitative discrimination of contrast
accessible versus inaccessible microvascular regions. Representative axial and coronal scans
from a pair of pig organs with or without one hour of autologous whole blood perfusion ex
vivo to simulate reperfusion injury demonstrate the utility of this mode of visualization to
assess regional variation in perfusion quality. For the delayed scan, Hounsfield units were
measured pixel by pixel in the first 8 mm of the renal cortex as a metric to evaluate cortical
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Fig. 4.1 Schematic and methodology of CT imaging to assess renal vasculature ex vivo.
(A) Ex vivo porcine kidney is placed inside of a CT scanner for imaging. (B) Imaging
sequence for kidneys during cold storage. (C) Maximum intensity projections are presented
the first three sequential scan in the cold storage imaging series. (D) Heat maps are presented
in axial and coronal views for a pair of porcine kidneys, with or without one hour of ex vivo
whole blood perfusion to simulate a period of reperfusion. Distributions from single slices
(left) and the full scans (right). (E) Background subtracted distributions and median values
are presented for the scans in (D).
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microvascular perfusion (Figure 4.1D). A histogram of the Hounsfield units was generated
and a background subtracted median was used as a measure of the quality of microvascular
perfusion (Figure 4.1E).
4.2 Angiography of transplant-declined human kidneys
Having optimized the imaging and assessment methods in porcine kidneys, I next imaged
a series of 6 transplant-declined human kidneys under an identical protocol. The 6 human
organs used for the study were recovered in coordination with the local organ procurement
organization (New England Donor Services) under an existing research protocol. The organs
were accepted in succession with no exclusion criteria on the basis of donor factors to provide
an unbiased evaluation of the utility of these methods to distinguish differences in viability
of transplant-declined human organs. Donor demographic details are provided in Table 4.1.
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Figure 4.2A depicts maximum intensity projections for the three consecutive scans of each
human organ. There was substantial variation in the dynamics of contrast accessibility
amongst the 6 organs (Figures 4.2A and B). The first organ in the series (Kidney 1) had the
highest rate of contrast filling. Notably, this organ was from a 22-year-old DCD donor with
a KDPI of 32 and had been accepted for transplantation. Unfortunately, an air pocket was
noted in the cold-perfusion circuit prior to transplant and the organ was declined for fear of
an air embolism in the kidney. The organ was otherwise healthy and viable for transplant.
Air emboli within the kidney were not observed upon imaging and the maximum intensity
projections appear to show good vascular access throughout the organ. Thus, this volumetric
assessment likely represents a standard for organs with high quality global perfusion.
In contrast, Kidney 5 and Kidney 6 displayed poor rates of initial contrast filling suggesting
substantial defects in the quality of global perfusion. Where the slope of contrast filling in
Kidney 1 was 2.1% ± 0.1% of the kidney volume filled per second, this slope dropped to
0.4% ± 0.04% and 0.3% ± 0.2% in Kidney 5 and Kidney 6 respectively. Thus, Kidney 5 and
Kidney 6 likely represent the poorer end of the spectrum with respect to the quality of initial
perfusion. These specific organs may not have been recoverable to a viable state for safe
transplantation. However, the ability to quantify the state of global perfusion in a robust way
can subsequently enable assessment of therapeutic strategies that would seek to restore the
perfusion of kidneys like Kidney 5 and Kidney 6 to a state similar to Kidney 1 using repeat
longitudinal measurements.
4.3 Regional microvascular accessibility assessment
Having evaluated the global metric of perfusion quality in the human organ series, the quality
of microvascular perfusion as determined by the end point scan was then assessed. These
images were segmented to remove all surrounding image artifact and pseudo-colored to
depict regions of hypoperfusion (blue) relative to well perfused regions (red). Representative
coronal and axial midpoint scans are displayed for qualitative visualization (Figure 4.3A).
In single slices throughout the scan, I was able to observe major differences in microvascular
perfusion (Figure 4.3A). These images demonstrate that the kidneys with faster filling rates of
the total vasculature have qualitatively more microvascular filling as evidenced by the clearly
visible increased area of red in the renal cortex in Kidney 1 and Kidney 4. Alternatively, the
kidneys with lower rates of initial filling, Kidney 5 and Kidney 6, have less or no contrast
enhancement in the cortex as evidenced by the predominantly blue images. Importantly,
Kidney 2, which had a higher initial filling rate, has relatively poor microvascular perfusion.
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Fig. 4.2 Angiography assessment of transplant-declined human kidneys. (A) 6 human
kidneys are presented as maximum intensity projections from each of the first 3 sequential
scans. Vascular volumes are calculated and plotted for all four scans in the series. (B) Slopes
from each vascular volume calculation are presented.
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Fig. 4.3 Assessment of regional microvascular accessibility in transplant-declined hu-
man organs. (A) Heat map representations (top) and histograms of Hounsfield units in
outer cortex (bottom) of single, midpoint axial and coronal slices from the end point scan
of 6 human kidneys imaged with the cold storage imaging protocol are presented. Heat
map ranges from blue representing the lower limit of enhancement to red, the upper limit of
enhancement. (B) Histograms of Hounsfield units from pooled slices throughout the scan are
presented for each kidney (left). Background subtracted medians are displayed (right).
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This highlights that these assessments reflect different components of organ perfusion (i.e.
global and regional perfusion quality).
Quantitative assessment of these images also supports what was qualitatively observed in
the pseudocolored scans from the center of the organ (Figure 4.3A and B). Hounsfield units
quantified per pixel in the first 8 mm of the cortex were measured in each slice of the full
scan before and 5 minutes after contrast was administered. The shifts (or lack thereof) in the
medians of the histograms from background reflect the quality of the cortical microvascular
perfusion (Figure 4.3A and B). Again, it is observed that Kidney 1 and Kidney 4 have the
highest levels of microvascular perfusion while Kidney 2, Kidney 3, Kidney 5, and Kidney 6
have little to no shift in Hounsfield units from the background measurement (Figure 4.3A
and B).
4.4 Imaging during normothermic machine perfusion
The preceding data demonstrates the capacity of contrast-enhanced CT to provide a quan-
titative whole-organ assessment. I next sought to determine the utility of this approach
for non-invasive, longitudinal evaluation of human kidneys during normothermic machine
perfusion (NMP). A pilot series of three human kidneys (Kidney 7, Kidney 8, Kidney 9) was
run to evaluate feasibility and determine the utility of contrast-enhanced CT in this setting.
The standard NMP circuit was adapted for use with a clinical CT scanner to enable imaging
during NMP [138]. With this approach, I was able to repeatedly obtain qualitative images of
organ vasculature during NMP (Figure 4.4A).
This pilot series also identified a key limitation with respect to using iohexol as the CT
contrast reagent for repeat longitudinal imaging during NMP. Specifically, a prolonged
persistence of the iohexol contrast reagent was identified within the organ following each
injection at different NMP time points. Evaluation of the four sequential scans performed
at each NMP time point showed a relatively slow clearance of the contrast from the tissue
after completion of iohexol injection. The 4th sequential organ scan, performed ~20 sec after
iohexol has cleared from the renal vein, routinely showed significant retention of iohexol
within the tissue parenchyma and all time points (Figure 4.4B and C). Moreover, a steady
build in the parenchymal levels of iohexol was observed in the initial scan performed at
each NMP time point (Figure 4.4D and E). This potential for continual buildup of iohexol
contrast reagent during NMP suggests that this approach does not meet the second criteria
for a non-invasive imaging modality to enable longitudinal measurements.
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Fig. 4.4 Contrast-enhanced CT imaging during NMP (A) Representative maximum in-
tensity projections of the large vessels from scan 2 are presented throughout 20 minutes of
NMP from Kidney 7 and Kidney 8. (B) Histograms of microvascular intensities from the
midpoint slice of Kidney 8 are presented from scans 1-4 at 20 minutes of NMP. (C) Heat
maps for Kidney 8 are displayed for scans 1-4 corresponding to the histograms presented
in (B). (D) Microvascular intensities from scan 1 are displayed throughout the 20 min of
NMP for Kidney 9. (E) Heat maps for the midpoint slices of Kidney 9 are presented for the
intensities presented in (D).
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4.5 Imaging before and after normothermic machine per-
fusion
To circumvent the challenge of iohexol retention, I returned to the cold-storage imaging
protocol to assess if iohexol could be effectively cleared with a flush of cold-lactated Ringers
solution (LR) following imaging. Indeed, it was observed that a 1L flush of cold LR reliably
removed iohexol to below the limits of detection (Figure 4.5). Thus, I next evaluated repeat
cold-storage imaging before and after NMP as a means to assess changes in quantitative
imaging parameters.
Fig. 4.5 Complete flush of contrast under cold-storage imaging conditions. Background
scans and corresponding histograms from Kidney 10 and Kidney 11 are presented.
Prior to initiation of NMP, both human kidneys in this series (Kidney 10, Kidney 11) were
each imaged with the standard cold-storage imaging protocol described above. Both organs
achieved high levels of contrast filling comparable to that achieved by Kidney 1 in the
preceding series (Figure 4.6A and B versus Figure 4.1A and B). Microvascular assessment,
as in Figure 4.3, similarly showed high levels of contrast accessibility with generally good
regional coverage; some relatively small pockets of hypoperfusion were observed similar
to Kidney 1 (Figure 4.6C and D). Collectively, these metrics suggest these organs were in a
relatively good state prior to NMP.
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Fig. 4.6 Contrast-enhanced CT before and after NMP. (A) Maximum intensity projections
are presented for Kidney 10 and Kidney 11 pre and post-NMP. The normalized fraction
of contrast volume is displayed for each scan (right). (B) Slopes of the contrast volume
calculated in (A) are presented pre and post-NMP for Kidney 10 and Kidney 11. Error is SD.
(C) Heat maps for single slices from the midpoint of the organ are displayed along with their
corresponding histograms. (D) Median values from the distribution of intensities within the
cortex throughout the entire organ are displayed for Kidney 10 (top) and Kidney 11 (bottom).
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Following the initial cold-storage imaging, the organs underwent 1 hr of NMP following the
standard clinical protocol previously developed by Hosgood and Nicholson[26]. Both organs
produced urine with Kidney 10 making 50 mL and Kidney 11 making 63 mL during the 1
hr perfusion period. In spite of making more urine, Kidney 11 had significantly impaired
renal blood flow (RBF) relative to Kidney 10 (Figure 4.7). This combination of higher urine
output with reduced RBF suggests a possible breakdown of glomerular barrier function.
Fig. 4.7 Organ perfusion parameters for Kidney 10 and Kidney 11. (A) Renal blood
flow (RBF) and urine output (B) are presented for Kidney 10 and Kidney 11.
Following NMP, both organs were again flushed with cold LR and cooled to 4°C under
static-cold storage for repeat imaging under identical conditions as prior to NMP. In the
repeat imaging series Kidney 10 had a slightly faster rate of contrast volume filling (2.4%
± 0.3% compared to 1.5% ± 0.2%), whereas Kidney 11 demonstrated no change. Notably,
the median Hounsfield unit of the organ parenchyma was significantly higher in Kidney
11 after NMP as compared to NMP (Figure 4.6C and D). Additionally, vasoconstriction of
the arterial vessels was also identified in Kidney 11 after NMP; vasoconstriction did not
appear in Kidney 10. The combination of higher median Hounsfield unit and vasoconstriction
following NMP was similar to that observed in a pig kidney perfused with whole blood (a
model of ischemia reperfusion injury; Figure 4.1D).
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Discussion
Ex vivo organ perfusion (including both hypothermic and normothermic variations) shows
great promise as a platform to enable improved viability assessment of higher-risk organs
[138–140]. As compared to a single biopsy collected from an organ under cold-storage,
organs on ex vivo perfusion can be repeatedly assessed for physiologic function over time.
At current, physiologic parameters like renal blood flow, vascular resistance, and urine
production (under normothermic conditions) are routinely measured in clinical utilization of
ex vivo perfusion [49, 26, 25, 128]. However, the utility of these basic parameters to guide
good clinical decision making has yet to be established. In fact, evidence to date suggests that
these parameters alone may not be reliable indicators of organ viability [119, 145]. Based on
this, as well as my clinically focused research experience, I propose that these parameters
may be necessary, but not sufficient, for effective organ evaluation. The underlying reason an
organ produces a high level of urine, for example, could be because the organ is functioning
well or because there has been a breakdown of glomerular barrier. Thus, there is a clear need
for complementary diagnostics that can contextualize these functional parameters.
Previous groups, evaluating ex vivo imaging modalities, have primarily been limited to
fluorescent imaging of animal organs [146, 147]. Here, I have evaluated the potential of ex
vivo tomography imaging for use as one of these complementary diagnostic assessments.
More specifically, contrast-enhanced CT was tested for two key criteria: (1) Capacity for
regional assessment of circulation within the whole-organ; and (2) Capacity for non-invasive,
longitudinal assessment in combination with NMP. The data demonstrate that contrast-
enhanced CT can be used for quantitative assessment of regional circulation across the
whole-organ (Criteria 1). I have further developed simple metrics to enable organ-to-organ
comparisons using this modality. With respect to Criteria 2, I have shown that contrast-
enhanced CT can potentially be used for longitudinal assessments in combination with
NMP. However, there are also some restrictions necessary to limit the invasiveness of this
procedure when using iohexol as the contrast reagent. Iohexol appeared to be retained
in kidneys when repeatedly administered under normothermic perfusion conditions; the
potential for nephrotoxicity of iohexol thus limits its use in this setting [148, 149]. However,
I demonstrated that it is possible to circumvent the issue of iohexol retention by administration
of iohexol under cold-storage conditions followed by extensive organ flushing.
It is beyond the scope of the current study to assess the safety and efficacy of ex vivo CT
for clinical assessment of marginal organs. Nevertheless, this study suggests that such
a future effort may be well worth considering. The example of Kidney 1, an otherwise
completely transplantable organ that went unused due to a suspected air embolus, showcases
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the potential. The ‘cold-storage-imaging’ approach developed here could possibly have been
used to visually identify if the embolus had entered the organ vasculature and, if so, to further
assess if extensive flushing could remove this. Additionally, the quantitative metrics could
provide critical context to the current standard measures of physiology described above to
enable clinicians to more effectively triage higher-risk organs. From a practical standpoint, it
will be essential to develop the ability to maintain optimal organ temperature and sterility
throughout the imaging procedure for this to become a clinically viable tool for assessment.
Contrast-enhanced CT imaging need not become a routine part of clinical care to still be
a valuable research tool. The research potential of this approach is demonstrated by the
vasoconstriction observed in both the pig kidney subjected to ischemia-reperfusion-injury
and Kidney 11. First, this type of observation can guide the generation of hypotheses for
future mechanistic studies to understand how organs respond to NMP. Moreover, if this
severe vasoconstriction following NMP were to be definitively identified as a marker of organ
injury, it could then be used to evaluate the efficacy of different therapeutic interventions
administered during NMP. It should also be noted that there is no restriction to the sole use
of iohexol as a contrast reagent or to CT as a sole imaging modality. There is a wide array
of different contrast agents that could be explored in future studies, including agents that
would remain within the vasculature to avoid the retention issue of iohexol. Additionally,
nuclear imaging (e.g. PET for assessment of metabolic function or SPECT for multi-isotope
molecular imaging of inflammatory markers) holds a great deal of promise in combination
with CT imaging; the scanner used for this study features both modalities.

Chapter 5
Summary
5.1 Revisiting Aims
In this section, I explore how the initial aims I set out to achieve throughout this body of
work were met.
1. Effectively deliver targeted nanoparticles during ex vivo NMP
In Chapter 1, I had demonstrated that it was possible to target nanoparticles to the vascular
endothelium during NMP. In well perfused organs, there was a significant targeting benefit.
In poorly perfused organs, NPs accumulated nonspecifically in red cell plugs. After develop-
ing a regimen to re-establish microvascular perfusion, endothelial targeted NPs showed a
significant targeting benefit even in long-cold stored organs. However, even in treated cases,
targeted NPs do not cover all of the microvasculature. This suggests that in future work,
we may need to consider changing the administered dose and/or modifying the targeting
capacity of the NPs.
2. Re-establish microvascular circulation in poorly perfused organs
Using a treatment regimen of tPA and plasminogen, I was able to effectively lyse microvas-
cular obstructions in human kidneys during NMP and re-establish microvascular circulation.
Not only did this enable better targeted drug delivery, it also lowered markers of tissue injury,
increased urine output, and stabilized kidney resistances.
3. Understand mechanisms by which microvascular obstructions arise
In this body of work I discovered that microvascular obstructions are rich in fibrinogen. Upon
the restoration of normothermia, sequestered fibrinogen in the tubular epithelia (that is cold
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storage dependent) is released into the vasculature and correlates with the appearance of
microvascular obstructions. While there may be other factors that contribute to the rise of
these microvascular obstructions, the translocation of fibrinogen into the vasculature appears
to be key mediator in poor organ perfusion seen in long-cold stored organs.
4. Investigate potential pre-transplantation therapeutic strategies to prevent IRI
Throughout the course of this thesis, I was able to investigate the role of an NLRP3 inflamma-
some inhibitor (MCC050) in IRI. I found that when delivered to human kidneys during NMP,
MCC950 had a protective effect up to 8 hours after the treatment was initially administered.
While there are many other therapeutic strategies available to investigate, MCC950 shows
significant promise.
5. Develop non-invasive imaging methods to visualize perfusion quality of whole organs
In most organ-based research, whole organ assessments are made based either on macroscopic
appearance or biopsy results. Here, I was able to successfully develop a high resolution
(600 µm), ex vivo imaging protocol utilizing CT to visualize vasculature integrity during
cold storage and NMP. Ultimately, this methodology can be adapted to utilize other contrast
agents or imaging platforms (e.g. positron emission tomography). As this approach is highly
customizable, I believe this advancement can be a valuable tool for organ research.
5.2 Future Directions
Having defined the conditions for effective NP targeting in an ex vivo setting and showing
that MCC950 is protective against IRI in the short term, the next logical step is to begin
formulating NPs with the small hydrophobic drug. To do so, it will be necessary to determine
the conditions (e.g organic:aqueous ratio, drug loading percentage, nanoprecipitation flow
rate) for optimal sustained release profiles of the NPs. Additionally, it will be necessary
to characterize the size, polydispersity index, and drug encapsulation efficiency of these
particles before tests can begin during renal NMP. It will be possible to utilize the ex vivo
imaging modalities developed throughout this thesis to ensure quality of perfusion and
desired protection from IRI in whole blood perfusion models.
The discovery that the accumulation of fibrinogen within the renal tubular epithelium in-
creases with cold storage time has led to more questions about “why organs fail” during cold
storage. Previously stored samples from our fibrinogen time course studies are currently
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being processed using multi-omic approaches (i.e. RNA sequencing and proteomics) to help
answer these questions. Through developing a more comprehensive understanding of how
organs respond to periods of cold stress, it should be possible to design better pre-transplant
therapeutics as I did with the tPA and plasminogen treatment regimen.
More immediately, I am working to establish a pilot trial of tPA and plasminogen treatment
in marginal kidneys with extended periods of cold preservation. In collaboration with Prof.
Nicholson, Dr. Hosgood, Dr. Tietjen, New England Donor Services, and the Yale Department
of Surgery, we plan to use this pilot trial in a series of 20 patients to determine the safety
and preliminary efficacy of transplanting tPA and plasminogen treated kidneys. Based on
the findings from my doctoral work, we believe that the successful implementation of this
treatment regimen will ultimately increase the rates of long-cold stored organ utilization
in renal transplantation and may further improve long-term viability of these organs. This
clinical trial will be the focus of my first year as a postdoctoral researcher at Yale, prior to
my enrollment in medical school as I pursue a career as an academic transplant surgeon.
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Appendix A
Materials and Methods
A.1 Chapter 1: Delivering targeted nanoparticles during
NMP
A.1.1 Ethical approvals
In vitro experimentation with HUVECs from de-identified sources has been classified as
nonhuman subject research by the Yale’s Institutional Review Board. Ethical approval for
experiments with human kidney was granted by the National Research Ethics Commission
in the United Kingdom. Consent for the use of the organs for research was obtained from the
donor family by the specialist nurses in organ donation before organ retrieval. Kidneys were
retrieved by one of the U.K. National Organ Retrieval Services teams. After in situ flushing
of the abdominal organs with cold preservation solution, kidneys were retrieved and then
stored by static cold storage. Eight kidneys that were deemed unsuitable for transplantation
were recruited into the study.
A.1.2 Materials
PLA-PEG copolymer (molecular weight, 16 to 5 kDa) was purchased from PolySciTech and
used as received without further purification. Anhydrous dimethyl sulfoxide (DMSO), DiI
and DiO stains, and Fisherbrand Superfrost Microscope Slides were purchased from Life
Technologies.Ulex vascular stain was purchased fromVector Laboratories either preconju-
gated with fluorescein isothiocyanate or unconjugated for later conjugation to AlexaFluor
633-N-hydroxysuccinimide following the vendor’s supplied protocol.
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A.1.3 NP formulation
NPs were prepared by a nanoprecipitation procedure [150]. PLA-PEG was dissolved at a
concentration of 100 mg/mL in DMSO and then diluted to the desired concentration for NP
formulation (typically about 55 mg/mL for about 165-nm NPs used in this study), along with
addition of either DiI or DiO dye also dissolved inDMSO. NPs were loaded with DiI or DiO
dye at a final dye/polymer ratio of 0.5% (w/w). The dye/polymer solution in DMSO was
added dropwise to vigorously stirringsterile deionized H2O (diH2O) in batches of 300 mL
of polymer/dye solution added to 1.2mL of diH2O, with identical repetitions performed to
generate a full NP batch. NPs were subsequently filtered through a 1.2-mm cellulose acetate
membrane (GE Healthcare Life Sciences) filter to remove any free-dye or polymer aggregates
and then pooled. The NP solutions were then transferred in batches to dialysis cassettes
(12-mL volume; molecular weight cutoff, 10,000; Slide-A-Lyzer, Thermo Fisher Scientific)
and dialyzed against two exchanges of about 2.2 liters of diH2O at room temperature to
remove excess DMSO. After dialysis, NPs were aliquoted and snap-frozen in liquid N2.
One aliquot from each NP batch was lyophilized in a preweighed tube to determine the
NP concentration. Standard NP concentration was typically about 5 mg/mL before Ab
conjugation.
A.1.4 Ab surface conjugation
Ab-conjugated PLA-PEG NPs were generated via 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide
hydrochloride-mediated COOH-NH2 coupling. Commercial Ab were purchased from BD
Biosciences (CD31, clone WM59; Isotype, clone MOPC-21) and subsequently dialyzed
overnight in dialysis cassettes (0.5 mL; molecular weight cutoff, 10,000; Slide-A-Lyzer,
Thermo Fisher Scientific) to remove sodium azide, which can inhibit the coupling reac-
tion. After dialysis, the protein concentration was adjusted (if necessary) to 0.55 mg/mL by
addition of sterile Dulbecco’s phosphate-buffered saline (Thermo Fisher Scientific).
A.1.5 Cell culture
HUVECs pooled from three separate donors were obtained from the Yale Vascular Biology
and Transplantation tissue culture core laboratory, where they were isolated from fresh
umbilical veins by treatment with collagenase and subsequently cultured in gelatin-coated
tissue culture plastic plates using M199 medium supplemented with 20% v/v fetal bovine
serum, 2% L-glutamine, 1% penicillin and streptomycin, and 1% (v/v) EC growth supplement
(fibroblast growth factor-1). All cell culture experiments were performed using cells passaged
A.1 Chapter 1: Delivering targeted nanoparticles during NMP 89
four or fewer times. For static NP incubation, cells were cultured for at least 4 to 5 days
after reaching full confluence to ensure the formation of mature cell-cell junctions to best
mimic in vivo conditions. The medium was exchanged every 2 to 3 days during these culture
periods to ensure that the cells remained viable. Cells were visually inspected before all
experiments to ensure cell viability.
A.1.6 Normothermic machine perfusion
After arrival, the kidneys were prepared, and the renal artery, vein, and ureter were cannulated.
The kidneys were weighed before undergoing ex vivo NMP [120, 138]. Briefly, the ex vivo
kidney perfusion circuit was designed using pediatric cardiopulmonary bypass technology
(Medtronic) and consisted of a centrifugal blood pump (Bio-Pump 560), a heat exchanger
(Chalice Medical), a venous reservoir (Medtronic), 1/4-inch polyvinyl chloride tubing, and
a Pixie membrane oxygenator (Medtronic). The hardware included a speed controller, a
TX50P flow transducer, and a temperature probe (Cole-Parmer). Two Alaris infusion pumps
(CareFusion) were also incorporated into the system. The circuit was primed with a perfusate
solution (Ringer’s solution, Baxter Healthcare) and one unit of ABO-compatible packed
red cells from the blood bank. Twenty-five milliliters of 10% mannitol (Baxter Healthcare),
8 mg of dexamethasone (Organon Laboratories), and 2 mL of heparin (1000 IU/mL; CP
Pharmaceuticals) were added to the perfusate. Sodium bicarbonate (8.4%; Fresenius Kabi)
was added to normalize the pH. A nutrient solution (NuTRIflex, B. Braun)with 25 mL of
8.4% sodium bicarbonate, 100 IU of insulin (Novo Nordisk), and multivitamins (Cernevit,
Baxter Healthcare) was infused into the circuit at a rate of 20 mL/hour. Prostacyclin (0.5 mg;
Flolan, GlaxoWellcome) was infused into the arterial arm of the circuit at a rate of 4mL/hour,
and 5%glucose (Baxter Healthcare) was infused at 7 mL/hour. Ringer’s solution was used to
replace urine output milliliter-for-milliliter.
Kidneys were perfused at a set mean arterial pressure (70 to 75 mmHg). The plasma-free
RBC-based perfusate was circulated from the venous reservoir through the centrifugal pump
into the membrane oxygenator, where it was oxygenated and also warmed to 36oC. It then
flowed through the arterial limb of the circuit to the renal artery. Venous return from the
renal vein was fed back into the reservoir [23]. Renal blood flow (RBF) was monitored
continuously during NMP, and the total urine output was recorded. Pre-perfusion wedge
biopsies and wedge biopsies were collected at various time points, as noted in Results. The
tissue was either fixed in 10% formal saline or snap-frozen in liquid nitrogen and then stored
at -80oC. Samples of perfusate and urine were also collected at the same time points and
stored at -80oC.
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The quality of each kidney was assessed on the basis of the macroscopic appearance, the
mean RBF, and the total amount of urine produced. For macroscopic assessment, each kidney
was categorized into one of three groups and scored according to its macroscopic appearance
as follows: (i) grade I, excellent perfusion (global pink appearance); (ii) grade II, moderate
perfusion (patchy pink and purple appearance, which either remained or improved during
NMP); (iii) grade III, poor perfusion (global mottling and purple and black appearance,
which remained throughout NMP). Kidneys with a mean RBF below the threshold (< 50
ml/min per 100 g) were given an additional score of 1. Kidneys producing less than the
threshold volume of urine (< 43 ml/hour) were also given an additional score of 1. Therefore,
overall NMP assessment scores can range from 1 (indicating the least injury) to 5 (the most
severe). Six of the eight kidneys enrolled in this study had an NMP assessment score of 2
(kidneys 1 to 5 and 8), whereas kidneys 6 and 7 had a score of 1.
A.1.7 Quantitative microscopy on tissue biopsy sample
Snap-frozen wedge biopsies were cryosectioned on a microtome to a thickness of either 10
or 20 µm. Sections were imaged without fixation to avoid any alteration in dye-loaded NP
signal. Ulex staining was performed rapidly with about 15 min of Ulex (Vector Laboratories)
conjugated with Alexa Fluor 633 (Life Technologies) after standard conjugation procedures.
After staining, sections were washed three times for 5 min each with DPBS and then mounted
with Hardmount medium (Vector Laboratories) and coverslipped. Independent images were
collected by raster scanning across cryosections, with typically three sections per condition
and typically at least seven or more images of regions containing glomeruli or solely inter-
stitial microvessels per section (corresponding to at least 15 images per section typically).
Images were sorted, filtered, and processed using custom MATLAB code to distinguish
glomerular vessels from surrounding microvasculature. Finally, the background-subtracted
NP fluorescent signal was quantified for each image; backgrounds were determined by imag-
ing sections from biopsies sampled before introduction of NP. For single-color experiments,
these intensity values were then normalized to the vascular area of each corresponding image,
as determined by Ulex staining. For two color experiments, the total background subtracted
signal from DiI (red) CD31-NPs was normalized to the DiO (green) isotype-NPs and ex-
pressed as a specificity ratio with 1 corresponding to nonspecific accumulations and values
> 1 corresponding to CD31-specific accumulation. Images were collected using a Semrock
GFP-1828A bandpass filter set (excitation, 470 to 495 nm; emission, 505 to 535 nm) and a
Chroma TRITC/DiI/Cy3 filter set (excitation, 525 to 550 nm; emission, 580 to 630 nm) with
an air immersion apochromatic 20× objective (NA, 0.95; Olympus) or 40× objective (NA,
0.90; Olympus) on an Olympus Z71 inverted microscope illuminated by a light-emitting
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diode (LED) light source (Olympus L300) with each LED at full illumination intensity.
These filter sets and illumination setup ensured no spectral bleed with these NPs, which is
a prerequisite for proper implementation of this technique. Quantitative equivalence of the
two color NPs was confirmed by adding concentrated NPs to the sample mounting medium
with minimal dilution. NPs were imaged in an identical plane as the positive Ulex stain to
ensure that any signal absorption would be identical to the standard imaging conditions. All
images were captured by an Olympus Retiga R6 CCD camera. Images of two-color NP
accumulation are presented as thresholded images so that regions of low and high levels of
accumulation can be equally appreciated. Data analysis, fitting, and statistical analysis were
performed in GraphPad Prism.
A.2 Chapter 2: Identifying and treating microvascular ob-
structions
A.2.1 Ethical Approvals
U.K. transplant declined kidneys
Consent for the use of transplant-declined kidneys for research was obtained from the donor
family by the specialist nurses in organ donation before organ retrieval. Consent for research
was obtained by The North East Newcastle & North Tyneside 2 research ethics committee
(15/NE/0408). Kidneys were retrieved by one of the U.K. National Organ Retrieval Services
teams. After in situ flushing of the abdominal organs with cold University of Wisconsin
preservation solution, kidneys were retrieved and then stored by static cold storage, packed in
ice. 23 kidneys that were deemed unsuitable for transplantation were recruited into the study.
Discard organ characteristics used in the experimental tPA series can be seen in Table 2.2
U.S. transplant declined kidneys
Prior to receiving any transplant-declined human kidneys donors and/or donor families
consented for their kidneys to be used for research through the New England Donor Services
(NEDS). In the U.S., since the donor is deceased, this research is not considered human
subject research as defined in the HHS Policy for Protection of Human Research Subjects 45
CFR 46.102. HIPAA is still invoked with these specimens and all kidneys used have been
de-identified from their deceased organ donors.
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Multi-center randomized control trial
Human renal cortex biopsies from 15 different donors of the multi-center randomized control
trial comparing cold storage to NMP (ISRCTN15821205) were taken from the control arm
(cold storage) before and 30 minutes after transplantation. These samples have been fixed
in 10% formalin. As the study is still ongoing, I currently do not have access to outcome
data. Donor characteristics can be see in Table 2.1. The study protocol and trial documents
including the consent form and participant information sheet have been approved by the
NHS Health Research Authority East of England, Cambridge Central Research Committee
(15/EE/0356). Approval has also been granted by the NHS Research & Development (R&D)
department and will be sought at each participating center [26].
A.2.2 Normothermic machine perfusion
After arrival, the kidneys were benched, and the renal artery, vein, and ureter were cannulated
with 14 Fr., 24 Fr., and 10 Fr cannula respectively. The kidneys were weighed before
undergoing ex vivo NMP in order to normalize perfusion parameters. Briefly, the ex vivo
kidney perfusion circuit was designed using pediatric cardiopulmonary bypass technology
(Medtronic) and consisted of a centrifugal blood pump (Bio-Pump 560), a heat exchanger
(Chalice Medical), a venous reservoir (Medtronic), 1/4-inch polyvinyl chloride tubing, and
a Pixie membrane oxygenator (Medtronic). The hardware included a speed controller, a
TX50P flow transducer, and a temperature probe (Cole-Parmer). Two Alaris infusion pumps
(CareFusion) were also incorporated into the system. The circuit was primed with a perfusate
solution (Ringer’s solution, Baxter Healthcare) and one unit of ABO-compatible packed
red cells from the blood bank. Fifteen milliliters of 10% mannitol (Baxter Healthcare),
6.67 mg of dexamethasone (Organon Laboratories), and 3 mL of heparin (1000 IU/mL; CP
Pharmaceuticals) were added to the perfusate. Sodium bicarbonate (8.4%; Fresenius Kabi)
was added to normalize the pH as necessary. Prostacyclin (0.5 mg; Flolan, Glaxo Wellcome)
was infused into the arterial arm of the circuit at a rate of 5 mL/hour, and 5% glucose (Baxter
Healthcare) was infused at 7 mL/hour. Ringer’s solution was used to replace urine output
milliliter-for-milliliter.
Kidneys were perfused at a set mean arterial pressure (75 to 85 mmHg). The plasma-free
RBC-based perfusate was circulated from the venous reservoir through the centrifugal pump
into the membrane oxygenator, where it was oxygenated and also warmed to 37oC. It then
flowed through the arterial limb of the circuit to the renal artery. Venous return from the
renal vein was fed back into the reservoir. Renal blood flow (RBF) was monitored every five
minutes during NMP, and the total urine output was recorded every thirty minutes. Cold
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storage wedge biopsies and perfusion wedge biopsies were collected at various time points,
as noted in tPA + plasminogen treatment. The tissue was either fixed in 10% formalin,
snap-frozen in liquid nitrogen and then stored at -80oC, or fixed in 2% glutaraldehyde, 2%
formaldehyde in a 0.1M sodium cacodylate buffer and stored at 4oC for TEM analysis.
Samples of perfusate and urine were also collected as noted , centrifuged at 1,300g and their
supernatants were snap frozen and stored at -80oC.
A.2.3 TEM imaging
The human kidney cortex biopsy taken after 30 min of NMP was immersion-fixed in 2.5%
glutaraldehyde and 2% paraformaldehyde in 0.1M cacodylate buffer (pH 7.4), then post-fixed
in 1% OsO 4 in the same buffer at room temperature for 1 hour. After en bloc staining with
2% aqueous uranyl acetate for 30 min, tissue was dehydrated in a graded series of ethanol
to 100%, followed by propylene oxide and finally embedded in EMBed 812 resin. Tissue
blocks were polymerized in 60oC oven overnight. Thin sections (60 nm) were cut by a Leica
ultramicrotome (UC7) and post-stained with 2% uranyl acetate and lead citrate. Sample grids
were examined in a FEI Tecnai transmission electron microscope at 80 kV of accelerating
voltage, digital images were recorded with an Olympus Morada CCD camera and iTEM
imaging software.
A.2.4 Fibrin(ogen) immunofluorescent staining
Frozen samples were cryosectioned to 4 µm and placed on Superfrost Plus glass slides
(Fisher). Samples were stored at -80oC until staining. Before staining, samples were air dried
for 10 min and a square was drawn around each sample with a hydrophobic pen. Samples
were treated with 1% paraformaldehyde for 10 min at room temperature, washed with PBS,
and then blocked with 10% fetal bovine serum for 30 min on ice. Samples were washed and
stained with 100 µg/mL of monoclonal mouse anti-human fibrin antibody (MyBioSource)
for 24 hours on ice. Samples were washed and stained with 8 µg/mL of 2° Ab (Alexa Fluor
546 goat anti-mouse IgM, Fischer) and 50 µg/mL of DyLight 649 Ulex for 1 hr. Samples
were then washed and air dried for 10 min. 10 µL of Vectashield Hard Set mounting media
were added to each sample preceding a coverslip. Mouse IgM (BioLegend) was used as an
isotype control. 2% bovine serum albumin was used to dilute all staining reagents.
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A.2.5 Fibrinogen protein levels
Snap-frozen kidney biopsies were thawed on ice and homogenized with an electric homog-
enizer in protein extraction and enhancement buffer (abcam). Levels of fibrinogen were
measured using a Human ELISA Kit (abcam) and normalized to protein levels measured
using a Pierce BCA protein assay kit (Thermofisher).
Fibrinogen protein presence and increase with CIT was also confirmed using Western blotting
techniques (Supplemental Figure 10). Kidney protein lysate diluted to 1500 µg/mL was
denatured at 100oC for 5 min with 25% beta-mercaptoethanol by volume. 20 µL of the
denatured protein and dye were added into the wells of the gel. 2 µL of pre-stained protein
ladder (abcam) was loaded into the gel. The 4-20% Mini-Protean TGX stain-free pre-
cast SDS gel (Bio-Rad Laboratories, Hercules, CA, USA) was run at 150 V for 1 hour in
SDS-PAGE buffer. Once the protein had migrated, it was transferred to a nitrocellulose
membrane using the mini Trans-Blot cell (Bio-Rad Laboratories, Hercules, CA, USA) in
transfer buffer (10% methanol, 190 M glycine, 25 mM Tris, pH 8.3) for 90 min at 90 V.
Nitrocellulose membranes were stained with Ponceau S solution to confirm protein transfer.
The nitrocellulose membranes were rinsed with1 X TBS-T (TBS; 50 mM Tris, 150 mM
NaCl, pH to 7.5. TBS-T; + 0.1% Tween-20) and blocked for 1 hour at RT in TBST + 5%
BSA. The membranes were stained overnight on a rocker at 4oC in TBS-T in 5% BSA
with anti-fibrinogen antibody (ab58207), mouse IgG1 (ab170190) for isotype control, or
alpha-tubulin as a house keeping gene to confirm equal loading levels of protein. Membranes
were washed 3x in TBST for 5 min/wash at RT. The next day, membranes were washed 4
times with TBS-T for 5 minutes before the addition of HRP-conjugated secondary antibody
(ab205719) in 5% milk in TBS-T and gently rocked at RT for 1 hour. After secondary Ab
incubation, wash steps were then repeated before membranes were incubated with 5 mL
ECL substrate per membrane for 1 minute (ab65623). The presence of chemiluminescent
bands (target protein) was visualized using the ChemiDoc MP imaging system (Bio-Rad
Laboratories, Hercules, CA, USA).
A.2.6 Microvascular obstruction quantification
In the series of 12 kidneys, 5 total biopsies were collected per organ: one prior to NMP, one
30 min after the start of NMP and before tPA treatment, and three at 90 min after the start of
NMP treatment. All biopsies were fixed in 10% formalin for 72 hours, embedded in paraffin,
and cut to 4 µm thicknesses. Sections were stained with a martius scarlet blue (MSB) kit
(tcs biosciences) to highlight erythrocytes (yellow), fibrin(ogen) (red), and collagen (blue)
within the samples. 20 images per section and 3 sections per sample were imaged with light
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microscopy for a robust quantification in experimental tPA work. Images were output in
2448 x 1920 pixels. Slides were imaged in a randomized, blinded fashion as to not bias
imaging fields. Images were collected in a snake-like pattern making sure not to overlap
fields of view.
To quantitatively and objectively assess the extent of vascular obstruction in each procured
sample, bright field images were analyzed with code that isolated the microvascular ob-
structions based on color. The extent of microvascular obstruction was quantified by the
total area of fibrin(ogen) (red with MSB stain) normalized to the total captured area (n = 20
regions per section). In order to ensure consistent color thresholding of the fibrin(ogen) stain
color across samples, a MATLAB (v. R2017b) script was developed that sorts individual
pixels by their RGB profile. In this program, the user provides initial input by identifying
fibrin(ogen)-positive and fibrin(ogen)-negative features in a set of representative sample
images. This input is used to generate a list of RGB profiles that are unique to pixels in
positive regions (positive color map), which is then applied to filter pixels in all other images
in the dataset. Each pixel is assigned a true or false score for fibrin(ogen) staining, generating
a fibrin(ogen)-positive binary mask of each image. Within individual organ donors, staining
was consistent (Figure 2.9). However, staining between organs tended to vary, even between
samples processed at the same time (Figure 2.10). To control for this, positive regions of
interest were identified for individual donors and used to create a color map for each donor.
A.2.7 tPA + plasminogen treatment
In order to test whether tPA in the presence of plasminogen was a viable agent to clear
microvascular obstructions in pre-transplant kidneys, tPA and plasminogen was administered
in a series of three single and three pairs of discarded human kidneys. tPA (altepase) was
obtained from Addenbrooke’s pharmacy in Cambridge. Plasminogen was purchased in
10-unit batches from Sigma Aldrich for use in a single perfusion circuit. NMP was performed
as described above with a few minor modifications. (1) 10 µg/mL of plasminogen was
added to the perfusate and allowed to circulate with the organ on circuit for 30 min prior
to the administration of tPA. (2) tPA was administered 30 min post start of perfusion via a
controlled infusion with 10% of the total dose delivered as a bolus into the arterial port and
90% of the dose delivered IV throughout the course of the hour-long treatment. tPA was
delivered at a dose of 100 µg/kg of graft. Single wedge biopsies were collected after a period
of cold storage, immediately prior to NMP, 30 min after the start of NMP while plasminogen
was circulating, and three wedge biopsies were taken 90 min after the start of NMP, 60 min
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after the initial dose of tPA was delivered. Wedge biopsies were minimized during NMP as
to not disrupt flow measurements.
A.2.8 Biochemical measurements
Biochemical assays were implemented to confirm the resolution of microvascular obstruc-
tions. The experiments performed also give possible insight into the mechanisms behind the
formation of microvascular obstructions. A plasmin activity assay (abcam) performed on
perfusate samples was used to assess tPA-mediated conversion of plasminogen to plasmin.
Fibrin degradation products were measured in the perfusate using a nonspecific Human
D-Dimer ELISA (abcam) to quantify the extent of fibrinopeptide degradation. All outcomes
were measured on a SpectraMax iD5 microplate reader. Perfusate samples, used for the
aforementioned assays, were centrifuged at 1,600g for 10 min in heparinized tubes to isolate
plasma immediately following collection, snap frozen in liquid nitrogen, and stored at -80oC
until testing. Wedge biopsies were snap frozen immediately after procurement, and were
homogenized following a pre-established protocol from abcam [151].
A.2.9 Nanoparticle administration
To determine how tPA and plasminogen treatment impacted targeted delivery, ICAM2
targeted-NPs were formulated and conjugated as previously described [74]. Targeted-NPs
(red) with control-NPs (green) were simultaneously injected into the arterial arms of the NMP
circuit upstream in three separate pairs of kidneys. One kidney in each pair received tPA and
plasminogen treatment while the other kidney underwent NMP without treatment. Biopsies
were collected at the end of CS, 30 min after NMP started (before tPA treatment), after an
hour of tPA treatment (before NP treatment), and after 4 hours of NP treatment. In each case,
NPs were injected for a final circulating concentration of 50 µg/mL of targeted-NPs and 50
µg/mL of control-NPs.
A.2.10 Quantitative fluorescent microscopy on tissue biopsy sample
Snap-frozen wedge biopsies were cryosectioned on a microtome to a thickness 16 µm.
Sections were imaged without fixation to avoid any alteration in dye-loaded NP signal.
Vascular staining was performed rapidly with 30 min of DyLight 649 labeled Ulex Europaeus
Agglutinin I (Vector Laboratories). After staining, sections were washed three times for 5
min each with DPBS and then mounted with Hardmount medium (Vector Laboratories) and
coverslipped.
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20 images of glomeruli or microvessels were collected for each of the three biopsies/kidney,
resulting in 60 total images for both glomeruli and microvessels in each kidney. The
background-subtracted NP fluorescent signal was quantified for each image; backgrounds
were determined by imaging sections from biopsies sampled before introduction of NP. The
total background subtracted signal from DiI (red) ICAM2-NPs was normalized to the DiO
(green) isotype-NPs and expressed as a specificity ratio with 1 corresponding to nonspecific
accumulations and values >1 corresponding to ICAM2 specific accumulation. Imaging
conditions were validated as previously described [74]. All fluorescent microscopy was
conducted with the Invitrogen EVOS FL Auto 2 Cell Imaging System.
A.2.11 Statistics
Distributions of kidney tissue images using quantitative microscopy did not follow normal dis-
tributions, so statistical analyses were performed using Wilcoxon signed-rank test. Significant
differences in biochemical measurements were assessed with multiple non-parametric-tests.
Differences in perfusion parameters were made with non-parametric paired t-tests, as the
experimental comparisons were made in matched kidneys. All statistical analyses were
conducted in Prism. 20 images per paraffin section were taken. Three paraffin sections per
sample were cut and imaged in all experimental series.
A.3 Chapter 3: NLRP3 inflammasome inhibition during
NMP
A.3.1 Murine renal ischemia reperfusion model
Animal husbandry
Female C57BL/6 (Charles River Laboratories, UK) and Nlrp3- derived from JAX stock
021302 (The Jackson Laboratory, USA) were maintained in pathogen free facilities with ad
libitum food and water in Central Biomedical Services at Addenbrooke’s Hospital site. All
procedures were conducted under Project License number P7720A3D6.
Pre-operative care
Pre-operative care was performed by surgical technicians working for University Biomedical
Services. Mice were anesthetized in an induction chamber using 5% isoflurane (Abbott
Laboratories, USA) with 2.0 L/min oxygen. Following induction, mice were transferred to
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a heating pad at 37oC and anesthesia was maintained with 1.5% isoflurane with 2.0 L/min
oxygen delivered via nose cone. The abdomen of the mouse was subsequently shaved using
electrical clipper and sterilized using ethanol and chlorhexidine (Molnlycke, Sweden). 0.1
mg/kg buprenorphine was administered for pain relief following surgery for non-terminal
procedures.
Surgery
Anesthetized mice were transferred from the pre-operative suite to the operating theater where
they were placed on a heating pad attached to a homeothermic monitoring system (Harvard
Apparatus, UK). Core temperature of the mice was monitored using rectal temperature probe.
Mice were maintained at 37.0 ± 0.5oC throughout the procedure. A midline laparotomy was
performed and the bilateral renal pedicles were dissected to expose the renal artery and veins.
All mice received 100 µL of either saline (n = 16) or 600 µg/mL of MCC950 (n = 4) injected
into the inferior vena cava using a 30 gauge needle. For mice that were set to receive renal
ischemic injury, 15mm microserrofine clamps (Fine Science Tools, Germany) were placed
over the renal hila of each kidney for 24 minutes to occlude renal blood flow. Successful
occlusion was confirmed through the development of a dark purple color in both kidneys.
During this period of ischemia, the midline laparotomy was closed using 5-0 absorbable
suture to maintain temperature. Following the period of ischemia, the clamps were removed
and return to normal color was confirmed, indicating successful reperfusion. For sham
operations (n = 8), the same procedure was mimicked but did not include the use of clamps.
All procedures were performed under sterile conditions.
Post-operative care
Mice were recovered in a heated cabinet for 24 hours and monitored hourly for the first six
hours to ensure proper wound healing at the site of incision. After 24 hours, mice were
anesthetized and prepared for terminal surgeries for bilateral kidney and blood collection.
Procedure randomization
Once consistent, and reproducible renal injury was established in a cohort of wild type mice
(n = 4), the four other conditions (1) wild type sham (n = 4), (2) NLRP3−/− sham (n = 4),
(3) wild type MCC950 + IRI (n = 4), and (4) NLRP3−/− IRI (n = 4) were conducted in a
random order using a random number generator.
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Sample collection and storage
Mice were allowed to recover for 24 hours prior to tissue and blood collection. These samples
were retrieved from the mice under terminal anesthesia. Approximately 500 µL of whole
blood was collected from the inferior vena cava using a 27 gauge needle attached to a 1-mL
syringe. Blood was transferred into 250 µL capillary action tubes and were temporarily
stored on ice prior to centrifugation. Blood was then spun on a 4oC table-top centrifuge for
10 minutes at 3000g. Serum was collected, snap frozen, and stored at -80oC until further
processing. Kidneys were excised from the mouse following blood collection. One randomly
assigned kidney in the pair was snap frozen in liquid nitrogen. Frozen tissue was stored in
cryovials at -80oC until further processing. The other kidney was placed in 10% neutral
buffered formalin and sent for paraffin embedding and H&E staining through Addenbrooke’s
histopathology services.
Sample processing
Mouse serum urea and creatinine levels were analyzed using enzymatic assays on the Siemens
Healthineers Dimension EXL clinical chemistry system using reagents supplied by Siemens
Healthineers (Newark, USA) at Addenbrooke’s Core Biochemical Assay Laboratory.
A.3.2 Transplant declined human kidney experiments
Consent for the use of transplant-declined kidneys for research was obtained from the donor
family by the specialist nurses in organ donation before organ retrieval. Consent for research
was obtained by The North East Newcastle & North Tyneside 2 research ethics committee
(15/NE/0408). Kidneys were retrieved by one of the U.K. National Organ Retrieval Services
teams. After in situ flushing of the abdominal organs with cold University of Wisconsin
preservation solution, kidneys were retrieved and then stored by static cold storage, packed
in ice. 12 kidneys that were deemed unsuitable for transplantation were recruited into the
study. Discard organ characteristics can be seen in Supplemental Table I. All organs in this
study were retrieved from donors following brain death.
Cold storage human organ culture for MCC950 dose titration
Human organ culture Upon organ receipt, biopsies were taken and dissected into 1
mm3 cubes in 37oC M199 media supplemented with 10% fetal bovine serum and 1%
penicillin streptomycin. Three 1 mm3 tissue sections were placed in a well in a 96-well
plate and incubated at 37oC and atmospheric O2 concentrations for 4 hours. with varying
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concentrations of MCC950 in 200 µL of supplemented M199 media. Samples were processed
in triplicate. Tissue was then transferred to a 96-well plate with 200 µL of gelatin veronal
buffer (Sigma-Aldrich) supplemented with 10% high panel reactive antibody serum (Tissue
Typing Lab, Addenbrooke’s). The plate was then placed in a hypoxic chamber with 5% O2
and incubated at 37oC for 2 hours. Following this period of hypoxia, tissue was transferred
back into another 96-well plate with complete M199 media and allowed to “reperfuse” under
normoxic conditions for 2 hours at 37oC.
Sample collection Following the period of reperfusion media and tissue samples were
collected and snap frozen. Samples were stored at -80oC until further processing.
Sample processing Using a 2X dilution IL-1β and IL-18 levels were measured in the
media using a human IL-1β ELISA (abcam, ab214025) and IL-18 ELISA (Generon, UK)
respectively.
MCC950 delivery during normothermic machine perfusion
Perfusion protocol Upon arrival, the kidneys were benched, and the renal artery, vein,
and ureter were cannulated with 14 Fr., 24 Fr., and 10 Fr cannula respectively. The kidneys
were weighed before undergoing ex vivo NMP in order to normalize perfusion parameters.
The ex vivo kidney perfusion circuit used was designed as previously noted. The circuit
was primed with a perfusate solution (Ringer’s solution, Baxter Healthcare) and one unit of
ABO-compatible packed red cells from the blood bank. Fifteen milliliters of 10% mannitol
(Baxter Healthcare), 6.67 mg of dexamethasone (Organon Laboratories), and 3 mL of heparin
(1000 IU/mL; CP Pharmaceuticals) were added to the perfusate. Sodium bicarbonate (8.4%;
Fresenius Kabi) was added to normalize the pH as necessary. Prostacyclin (0.5mg; Flolan,
Glaxo Wellcome) was infused into the arterial arm of the circuit at a rate of 5 mL/hour, and
5% glucose (Baxter Healthcare) was infused at 7 mL/hour. Ringer’s solution was used to
replace urine output milliliter-for-milliliter. Kidneys were perfused at a set mean arterial
pressure (75to 85mmHg). The plasma-free RBC-based perfusate was circulated from the
venous reservoir through the centrifugal pump into the membrane oxygenator, where it was
oxygenated and also warmed to 37oC. It then flowed through the arterial limb of the circuit
to the renal artery. Venous return from the renal vein was fed back into the reservoir.
Renal blood flow (RBF) was monitored every five minutes for the first 90 minutes of NMP to
monitor the stabilization of the organ and then every 30 minutes for the remaining 4 hours of
perfusion. The total urine output was recorded every thirty minutes.
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MCC950 injection After 90 minutes of perfusion, allowing the organ to stabilize a 10
mL bolus of 20 mg of MCC950 was injected into the arterial arm of the perfusion circuit
upstream of the kidney in the treated condition. This lead to a final concentration of 100
µM of MCC950 in the circulating perfusate. In the untreated condition, 10 mL of saline was
injected into the arterial arm as a control.
Sample collection and storage Wedge biopsies were collected prior to perfusion, at 90
minutes of perfusion (prior to treatment), and at the end of the 5.5 hour long perfusion.
Biopsies were divided and the tissue was either fixed in 10% formalin or snap-frozen in
liquid nitrogen and then stored at -80oC. Samples of perfusate were collected prior to the
organ being connected to the circuit, at 90 minutes of perfusion (prior to treatment), and at
the end of the 5.5 hour long perfusion. Urine samples were collected at 90 minutes and 5.5
hours of perfusion. Perfusate and urine samples were centrifuged at 1,300g for 10 minutes at
4oC. Supernatants were aliquoted, snap frozen, and stored at -80oC until further analysis.
Sample processing The perfusate cytokine levels were analyzed by an electrochemilu-
minescence assay using the MesoScale Discovery (MSD) human Proinflammatory Panel 1
(MSD, Rockville, MD, USA) at Addenbrooke’s Core Biochemical Assay Laboratory. This
assay is a 10-plex sandwich immunoassay with an electrochemical detection system which is
read of the MSD S600 reader.
Post-perfusion human organ culture Following the 5.5 hour period of perfusion, biopsies
were dissected into 1 mm3 cubes in 37oC supplemented M199 media. Tissue was then
immediately transferred to the hypoxic conditions followed by the reperfusion conditions as
previously described.
A.3.3 Statistics
All statistical analyses were conducted in Prism.
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A.4.1 Porcine organ recovery, preservation, and perfusion
30 porcine kidneys were used to develop CT imaging methods under conditions of cold
storage and normothermic machine perfusion. Methods were initially established in a
series of porcine kidneys obtained from a local slaughterhouse post-mortem. Once imaging
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protocols were finalized, imaging was conducted in a series of porcine kidneys under our
experimental control. Protocols for the care of all experimental animals in this study were
approved by Yale IACUC and were designed to comply with The Guide for the Care and
Use of Laboratory Animals, by the National Research Council (US) Institute for Laboratory
Animal Research. Kidneys were procured using a DCD model of procurement. Animals
were sedated, intubated, and maintained under general anesthesia until they were euthanized.
Dissections were based on clinical DCD procurement procedures. The infrarenal aorta and
inferior vena cava (IVC) were exposed, then the pigs were euthanized with phenobarbital.
After a period of either minimal (0-5 min) or long (30 min) warm ischemia, the aorta was
cannulated and flushed with 4-6 L of Custodiol HTK. The infrarenal cava was released in the
abdomen, suprahepatic cava released in the chest, and descending thoracic aorta clamped.
Flushing proceeded until effluent from the IVC cleared. Kidneys were subsequently procured
en block and benched on the back table. The renal artery (RA) and ureters were cannulated
(Cole-Parmer 1/8” – 1/4” leur lock adapter for the RA, and 14 Fr silicone catheter for the
ureter) and flushed with an additional 0.5 L of Custodiol HTK and the kidney stored in
preservation solution on ice comparable to clinical standard cold storage (SCS) until imaging
or perfusion. Immediately prior to imaging, the kidneys were flushed with 500 mL of cold
lactated ringer’s (LR) to remove the preservation solution. To simulate reperfusion injury,
porcine kidneys were perfused with autologous blood for 1 hour following well established
experimental protocols [144].
A.4.2 Human organ recovery and preservation
11 transplant-declined human kidneys were obtained for imaging. 6 were used for cold
storage imaging only, 3 for a pilot imaging series during NMP, and 2 for the pre/post NMP
series. Transplant-declined human kidneys were obtained under a protocol approved by
New England Donor Services (NEDS). Consent for the use of the organs for research was
obtained from donor families by organ donation nurse specialists. Kidneys were retrieved
by clinical organ recovery teams. After in situ flushing of the abdominal organs with cold
preservation solution, kidneys were retrieved and stored by clinical protocols by either static
cold storage, or hypothermic machine perfusion (LifePort Kidney Transporter from Organ
Recovery Systems®, Itasca, IL). No specific selection criteria were applied to organ offers
from NEDS and kidneys from both brain death and cardiac death donors were utilized.
Donor demographic and organ characteristics for kidneys used in the experimental series are
reported in Table 1. On arrival to the lab, kidneys were stored in ice in a 4oC refrigerator
in the preservation solution they were delivered. The kidneys were dissected to remove
extrarenal fat. The renal artery (RA) and ureters were cannulated with a size appropriate
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cannula (Cole-Parmer 1/8”-1/4” leur lock adapter, or cannula from hypothermic perfusion
for the RA and 14Fr silicone catheter for the ureter). Kidneys were then stored under static
cold conditions until imaging.
A.4.3 Computed tomography imaging protocols
All CT imaging was performed on a 64-slice GE clinical CT scanner at the Yale Translational
Research Imaging Center. All imaging series utilized whole organ, helical scans and were
obtained at 250mA and 80kEv. Contrast infusions were performed using a clinical contrast
injector (MEDRAD Stellant Injection System). Custom MATLAB code was developed for
image analysis to supplement analysis performed in HOROS, a freeware software package
for analysis of dicom images.
A.4.4 Cold storage imaging
Cold storage imaging was performed on a setup where the contrast and crystalloid were
infused using the clinical contrast infuser connected to a 3-way stopcock on the renal artery
cannula. The other port on the 3-way stop cock was connected to a bag of cold LR, used to
flush the preservation solution from the organ prior to imaging. The organ was positioned
on a urocatch bag (Universal Medical) secured over a plastic container with renal vein
extending away from the hilum to allow for contrast to passively drain away from the organ.
Immediately prior to imaging, the kidneys were flushed with 500 mL of cold LR to remove the
preservation solution. 5% iohexol contrast was infused at 1 mL/second for 50 seconds. When
contrast infusion began, three sequential scans were obtained to capture major renal vascular
filling. After a 5-minute delay, a fourth helical scan was obtained to capture microvascular
deficits.
A.4.5 Normothermic machine perfusion imaging
Methods for perfusion imaging were developed with human kidneys 7-9. During the cold
storage imaging prior to NMP, total contrast infused was reduced to 15 mL from 50 mL in
an attempt to avoid oversaturating the organ. The kidneys were perfused for 30 minutes
using an NMP protocol adapted from a well-established protocol [26]. During NMP imaging,
contrast was delivered at 3 mL/second for 15 seconds. Repeat whole organ helical scans
were obtained with before NMP (during cold-storage) and after ~5, ~10, ~20 min of NMP
for HK07 and HK08; HK09 was measured at ~5, 10, 15 and 20 min after initiation of NMP.
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A.4.6 Pre and post NMP imaging
The cold storage imaging protocol was used before and after NMP to identify the impact of
the procedure on organ circulation. The pre-NMP imaging was performed as described in the
cold storage section above. Following imaging, the kidney was flushed with 1L of cold LR
to remove contrast. It was then perfused using NMP on a custom adapted pediatric cardiac
bypass circuit in our lab as descried elsewhere for 1 hour while recording pressure, flow, and
urine output. The kidney was then flushed with LR until effluent cleared, and was stored for
1 hour using SCS. Prior to repeat imaging, the kidney was flushed with 500 mL of cold LR
and again imaged with the cold storage imaging protocol.
A.4.7 Statistics
All statistical analyses were conducted in Prism.
Appendix B
Supplementary Code
B.1 MATLAB code for two-color fluorescent microscopy
quantification
function [ vasc ] = vasc_filter_2c_roi()
%Program to isolate glomerular versus microvasculature for kidney quantitation
%This version is for two color analysis
warning(’off’, ’Images:initSize:adjustingMag’);
close all;
%Get file and read in ulex channel
[FileName,PathName,FilterIndex] = uigetfile(’.tif’);
cd(PathName);
cd ..;
d = dir;
for j = 3:length(d)
cd(d(j).name);
vasc.FileName = strcat(d(j).name,’_MMStack_Pos0.ome.tif’);
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vasc.ulex.ui16 = imread(vasc.FileName,4);
vasc.ulex_threshold = graythresh(vasc.ulex.ui16)*2^16;
vasc.h = size(vasc.ulex.ui16,1);
vasc.w = size(vasc.ulex.ui16,2);
%Generate black and white image
vasc.ulex.bw = imbinarize(vasc.ulex.ui16,vasc.ulex_threshold/2^16);
colormap(’gray’);
vasc.ulex.adj = imadjust(vasc.ulex.ui16.*uint16(vasc.ulex.bw),[300 4000]/2^16);
vasc.ulex.bw_r = uint16(cat(3,vasc.ulex.bw,zeros(2200,2688),
zeros(2200,2688))*2^16);
vasc.ulex.adj_w = cat(3,vasc.ulex.adj, vasc.ulex.adj, vasc.ulex.adj);
imshow(vasc.ulex.bw_r+vasc.ulex.adj_w);
glom_roi = input(’Are there glomeruli? (1==yes, enter for no): ’);
if glom_roi == 1
regofint = roipoly();
vasc.ulex.glom.regofint = regofint;
vasc.ulex.microv.regofint = abs(1-regofint);
vasc.ulex.glom.bw = vasc.ulex.bw.*vasc.ulex.glom.regofint;
vasc.ulex.glom.ui16 = vasc.ulex.ui16.*uint16(vasc.ulex.glom.bw);
vasc.ulex.microv.bw = vasc.ulex.bw.*vasc.ulex.microv.regofint;
vasc.ulex.microv.ui16 = vasc.ulex.ui16.*uint16(vasc.ulex.microv.bw);
imshow(vasc.ulex.glom.bw);
title(sprintf(’Thresh = %d’, round(vasc.ulex_threshold)));
pause;
close all;
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else
regofint = zeros(2200,2688);
vasc.ulex.glom.regofint = regofint;
vasc.ulex.microv.regofint = abs(1-regofint);
vasc.ulex.glom.bw = zeros(2200,2688);
vasc.ulex.glom.ui16 = zeros(2200,2688);
vasc.ulex.microv.bw = vasc.ulex.bw;
vasc.ulex.microv.ui16 = vasc.ulex.ui16;
close all;
end
%Save vasc variable to vasc.mat
save vasc.mat vasc;
cd ..;
end
end
function [ np, data] = np_quantify_2cv2( np_background, np_thresh, scale )
%Program for quantification of NP signal in two color HK3-5
%experiments
%Input np_background and np_threshold as [dii dio]
%scale input is in terms of micron per pixel
%Navigate to parent folder of images then sequential move to image folder
%and load image and vasc filter mat file
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warning(’off’, ’Images:initSize:adjustingMag’);
np.dii.np_background = np_background(1);
np.dio.np_background = np_background(2);
[FileName,PathName,FilterIndex] = uigetfile(’.tif’);
cd(PathName);
cd ..;
d = dir;
np.data = zeros(length(d)-2,3);%Image number; area; mean
for j = 3:length(d)
cd(d(j).name);
np.FileName = strcat(d(j).name,’_MMStack_Pos0.ome.tif’);
np.dii.ui16 = imread(np.FileName,3);
np.dio.ui16 = imread(np.FileName,2);
load vasc.mat;
np.dii.thresh = np_thresh(1);
np.dio.thresh = np_thresh(2);
np.dii.ui16_bw = imbinarize(np.dii.ui16, np.dii.thresh/2^16);
np.dio.ui16_bw = imbinarize(np.dio.ui16, np.dio.thresh/2^16);
%Parse NP image for glom v microv
np.dii.glom.ui16 = uint16(vasc.ulex.glom.regofint).*np.dii.ui16;
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np.dii.glom.bw = vasc.ulex.glom.regofint.
*imbinarize(np.dii.ui16,np.dii.thresh/2^16);
np.dii.glom.ui16_thresh = uint16(np.dii.glom.bw).*np.dii.glom.ui16;
np.dii.microv.ui16 = uint16(vasc.ulex.microv.regofint).*np.dii.ui16;
np.dii.microv.bw = vasc.ulex.microv.regofint.
*imbinarize(np.dii.ui16,np.dii.thresh/2^16);
np.dii.microv.ui16_thresh = uint16(np.dii.microv.bw).*np.dii.microv.ui16;
np.dio.glom.ui16 = uint16(vasc.ulex.glom.regofint).*np.dio.ui16;
np.dio.glom.bw = vasc.ulex.glom.regofint.
*imbinarize(np.dio.ui16,np.dio.thresh/2^16);
np.dio.glom.ui16_thresh = uint16(np.dio.glom.bw).*np.dio.glom.ui16;
np.dio.microv.ui16 = uint16(vasc.ulex.microv.regofint).*np.dio.ui16;
np.dio.microv.bw = vasc.ulex.microv.regofint.
*imbinarize(np.dio.ui16,np.dio.thresh/2^16);
np.dio.microv.ui16_thresh = uint16(np.dio.microv.bw).*np.dio.microv.ui16;
np.np_overlay.glom.bw = uint16(cat
(3,np.dii.glom.bw, np.dio.glom.bw, zeros(2200,2688)))*2^16;
np.np_overlay.microv.bw = uint16(cat(
3,np.dii.microv.bw, np.dio.microv.bw, zeros(2200,2688)))*2^16;
%Calculate background subtracted mean pixel intensity
np.dii.glom.dist = np.dii.glom.ui16_thresh
(np.dii.glom.ui16_thresh~=0)-np.dii.np_background;
np.dii.microv.dist = np.dii.microv.ui16_thresh
(np.dii.microv.ui16_thresh~=0)-np.dii.np_background;
np.dio.glom.dist = np.dio.glom.ui16_thresh
(np.dio.glom.ui16_thresh~=0)-np.dio.np_background;
np.dio.microv.dist = np.dio.microv.ui16_thresh
(np.dio.microv.ui16_thresh~=0)-np.dio.np_background;
np.dii.glom.mean = mean(np.dii.glom.dist);
np.dii.microv.mean = mean(np.dii.microv.dist);
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np.dio.glom.mean = mean(np.dio.glom.dist);
np.dio.microv.mean = mean(np.dio.microv.dist);
np.dii.glom.area = numel(np.dii.glom.dist)*scale^2;
np.dii.microv.area = numel(np.dii.microv.dist)*scale^2;
np.dio.glom.area = numel(np.dio.glom.dist)*scale^2;
np.dio.microv.area = numel(np.dio.microv.dist)*scale^2;
np.dii.glom.total = np.dii.glom.mean*np.dii.glom.area;
np.dii.microv.total = np.dii.microv.mean*np.dii.microv.area;
np.dio.glom.total = np.dio.glom.mean*np.dio.glom.area;
np.dio.microv.total = np.dio.microv.mean*np.dio.microv.area;
save np.mat np;
data.glom(j-2,1) = j-2;
data.glom(j-2,2) = np.dii.glom.area;
data.glom(j-2,3) = np.dio.glom.area;
data.glom(j-2,4) = data.glom(j-2,2)/data.glom(j-2,3);
data.glom(j-2,5) = np.dii.glom.mean;
data.glom(j-2,6) = np.dio.glom.mean;
data.glom(j-2,7) = data.glom(j-2,5)/data.glom(j-2,6);
data.glom(j-2,8) = np.dii.glom.total;
data.glom(j-2,9) = np.dio.glom.total;
data.glom(j-2,10) = np.dii.glom.total/np.dio.glom.total;
data.glom(j-2,11) = nnz(vasc.ulex.glom.bw)*scale^2;
data.glom(j-2,12) = np.dii.glom.total/data.glom(j-2,11);
data.glom(j-2,13) = np.dio.glom.total/data.glom(j-2,11);
data.microv(j-2,1) = j-1;
data.microv(j-2,2) = np.dii.microv.area;
data.microv(j-2,3) = np.dio.microv.area;
data.microv(j-2,4) = data.microv(j-2,2)/data.microv(j-2,3);
data.microv(j-2,5) = np.dii.microv.mean;
data.microv(j-2,6) = np.dio.microv.mean;
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data.microv(j-2,7) = data.microv(j-2,5)/data.microv(j-2,6);
data.microv(j-2,8) = np.dii.microv.total;
data.microv(j-2,9) = np.dio.microv.total;
data.microv(j-2,10) = np.dii.microv.total/np.dio.microv.total;
data.microv(j-2,11) = nnz(vasc.ulex.microv.bw)*scale^2;
data.microv(j-2,12) = np.dii.microv.total/data.microv(j-2,11);
data.microv(j-2,13) = np.dio.microv.total/data.microv(j-2,11);
cd ..
end
save data.mat data;
save np.mat np;
end
B.2 MATLAB code to ’create color map’ on brightfield im-
ages
%load images and select pos/neg regions
close all
clear all
images = [dir(’*02.tif’); dir(’*03.tif’)];
%loads images but does not read them yet
for ii = 1:length(images)
img_name = images(ii).name;
info = imfinfo(img_name);
img.ui8 = imread(img_name);
img.height = size(img.ui8,1);
img.width = size(img.ui8,2);
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temp.ui8_r = uint8(img.ui8(:,:,1));
temp.ui8_g = uint8(img.ui8(:,:,2));
temp.ui8_b = uint8(img.ui8(:,:,3));
f1 = figure(1);
f1.Units = ’normalized’;
f1.OuterPosition = [0 0.2 0.9 0.8];
imshow(img.ui8)
% select first positive region
h = msgbox(’Select positive region 1’);
uiwait(h);
findposreg1 = roipoly();
img.findposreg1 = findposreg1;
% select second positive region
h = msgbox(’Select positive region 2’);
uiwait(h);
%display(’Select positive region 2’)
findposreg2 = roipoly();
img.findposreg2 = findposreg2;
% make array where 1 is in selected positive regions and 0 is not
img.index_pos = img.findposreg1 + img.findposreg2;
% make index of the linear index of selected positive pixels
idx_pos = sort(unique(cat(1,find(img.findposreg1),find(img.findposreg2))));
% select first negative region
h = msgbox(’Select negative region 1’);
uiwait(h);
findnegreg1 = roipoly();
img.findnegreg1 = findnegreg1;
% select second negative region
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h = msgbox(’Select negative region 2’);
uiwait(h);
findnegreg2 = roipoly();
img.findnegreg2 = findnegreg2;
% make array where 1 is in selected negative regions and 0 is not
img.index_neg = img.findnegreg1 + img.findnegreg2;
% make index of the linear index of selected negative pixels
idx_neg = sort(unique(cat(1,find(img.findnegreg1),find(img.findnegreg2))));
% convert to an indexed image with a colormap, display image
if ii == 1
display(’generating color map’)
[X,map] = rgb2ind(img.ui8,65536);
%second input in this function is the number of colors
%will run faster with fewer colors but you will get more false negative pixels
else
display(’using previous color map’)
X = dither(img.ui8,map,8,7);
end
storeX = X;
% find all colors from colormap in both positive and negative selected
% regions
poscolors = sort(unique(X(idx_pos)));
negcolors = sort(unique(X(idx_neg)));
% make a list of all colors that
nooverlap = poscolors(find(-1*(ismember(poscolors,negcolors) - 1)));
for ll = 1:(size(X,1)*size(X,2))
if ismember(X(ll),nooverlap) == 0
X(ll) = 0;
else
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continue
end
end
storedPosColors(1:length(nooverlap),ii) = nooverlap;
end
PosColorList = unique(nonzeros(reshape(storedPosColors,[],1)));
save(’PosColors.mat’,’PosColorList’);
save(’RefColorMap.mat’,’map’);
f2 = figure(2);
f2.Units = ’normalized’;
f2.OuterPosition = [0 0.2 0.9 0.8];
imagesc(X)
colormap(map)
axis image
colorbar
B.3 MATLAB code to quantify positive area in brightfield
images
close all
clear all
images = dir(’*.tif’); %loads images but does not read them yet
%select what you want to do, 1=true, 0=false
save_images = 0;
load(’PosColors.mat’);
load(’RefColorMap.mat’);
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for ii = 1:length(images)
imageNumber_outOf = [ii length(images)];
imageNumber_outOf
img_name = images(ii).name;
info = imfinfo(img_name);
img.ui8 = imread(img_name);
img.height = size(img.ui8,1);
img.width = size(img.ui8,2);
img_area = img.height*img.width;
indimage = dither(img.ui8,map,8,7);
for ll = 1:(size(indimage,1)*size(indimage,2))
if ismember(indimage(ll),PosColorList) == 0
indimage(ll) = 0;
else
continue
end
end
% convert indexed image to mask (zeros and ones)
mask_idx = find(indimage);
maskzeros = zeros(img.height,img.width);
maskzeros(mask_idx) = 1;
% dilate, erode ,fill holes in mask
SE = strel(’disk’,5,4);
dilated = imdilate(maskzeros,SE);
eroded = imerode(dilated,SE);
filledBWmask = imfill(eroded,’holes’);
conncomp = bwconncomp(filledBWmask);
numPixels = cellfun(@numel,conncomp.PixelIdxList);
img.stain = zeros(img.height, img.width);
for kk = 1:conncomp.NumObjects
if numPixels(kk) > 50
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img.stain(conncomp.PixelIdxList{kk}) = 1;
end
end
% calculate the positive pixel number
pos_area = nnz(img.stain);
% make mask green
filledgreenmask = uint8(cat(3,zeros
(img.height,img.width),img.stain,zeros(img.height,img.width))*2^8);
fig = figure(3);
fig.Units = ’normalized’;
fig.OuterPosition = [0 0.2 0.8 0.8];
subplot(4,2,[1,4]), imshow(filledgreenmask+img.ui8);
subplot(4,2,[5,8]), imshowpair(filledgreenmask,img.ui8,’montage’);
% save images
if save_images == 1
picturename = sprintf([img_name(1:end-4) ’_detected_stain’]);
saveas(gcf, picturename,’tif’);
end
% store image name, positive pixels, total pixels in Results table
Results(ii,1) = {img_name};
Results(ii,2) = {pos_area};
Results(ii,3) = {img_area};
Results(ii,4) = {pos_area/img_area};
end
save(’Results.mat’,’Results’);
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B.4 MATLAB code to quantify vascular area in a DICOM
images
%clear all
close all
CT_images = dir(’*.dcm’);
info = dicominfo(CT_images(1).name);
pixelSize = info.PixelSpacing(1);
voxel_size = 0.625*pixelSize^2; % in mm
BG_img_file_name = CT_images(157).name; % change accordingly
BG_img = dicomread(BG_img_file_name);
start_frame = 1; % change accordingly
end_frame = 157; % change accordingly
radius = 100
plot_figures = 1;
find_center = 1;
select_one_region = 0;
select_two_regions = 0;
cut_out_region = 0;
%find organ center
if find_center == 1
s = round((end_frame-start_frame+1)/2);
img_name = CT_images(s).name;
img = dicomread(img_name);
figure(1), imshow(imadjust(img,[0.5 0.53],[]))
h = msgbox(’Select image region which should be cut out’);
display(’Select image region which should be cut out’)
region = roipoly();
neg_region = abs(1-region);
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img_BGsub = img-BG_img;
img_BGsub(img_BGsub < 0) = 0;
thresh_organ = graythresh(img_BGsub);
img_BGsub_organ_bw = imbinarize(img_BGsub,thresh_organ);
CC = bwconncomp(img_BGsub_organ_bw);
numPixels = cellfun(@numel, CC.PixelIdxList);
[biggest, idx] = max(numPixels);
img_BGsub_organ_bw = zeros(512,512);
img_BGsub_organ_bw(CC.PixelIdxList{idx}) = 1;
img_BGsub_organ = img_BGsub_organ_bw.*double(img);
img_BGsub_organ = img_BGsub_organ.*double(neg_region);
figure(3), imshow(img_BGsub_organ_bw)
img_BGsub_organ_cr = bwconncomp(img_BGsub_organ);
c = regionprops(img_BGsub_organ_cr,’centroid’);
xCenter = c.Centroid(1);
yCenter = c.Centroid(2);
figure(2), imshow(img_BGsub_organ)
hold on
plot(xCenter,yCenter,’r+’);
end
%real program starts
for i = start_frame:end_frame;%1:length(CT_images)
img_name = CT_images(i).name;
img = dicomread(img_name);
if plot_figures == 1
figure(1), imshow(imadjust(img,[0.5 0.53],[]))
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end
img_BGsub = img-BG_img;
img_BGsub(img_BGsub < 0) = 0;
thresh_organ = graythresh(img_BGsub);
img_BGsub_organ_bw = imbinarize(img_BGsub,thresh_organ);
CC = bwconncomp(img_BGsub_organ_bw);
numPixels = cellfun(@numel, CC.PixelIdxList);
ecc = regionprops(CC, ’Eccentricity’);
ecc = struct2cell(ecc);
[biggest, idx] = max(numPixels);
if select_one_region == 0;
for j = 1:length(CC.PixelIdxList)
if numPixels(j) > 1000
img_BGsub_organ_bw(CC.PixelIdxList{j}) = 1;
else img_BGsub_organ_bw(CC.PixelIdxList{j}) = 0;
end
end
end
if select_one_region == 1
region = roipoly();
img_BGsub_organ_bw = region.*img_BGsub_organ_bw;
end
if select_two_regions == 1
region1 = roipoly();
region2 = roipoly();
region = region1+region2;
img_BGsub_organ_bw = region.*img_BGsub_organ_bw;
end
if cut_out_region == 1
region3 = roipoly();
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neg_region3 = abs(1-region3);
img_BGsub_organ_bw = neg_region3.*img_BGsub_organ_bw;
end
img_BGsub_organ = img_BGsub_organ_bw.*double(img);
img_BGsub_organ = img_BGsub_organ.*double(neg_region);
organ_volume(i) = nnz(img_BGsub_organ)*voxel_size;
if plot_figures == 1
figure(2), imshow(img_BGsub_organ)
end
img_BGsub_vasc = img_BGsub_organ - 1100;
img_BGsub_vasc(img_BGsub_vasc < 0) = 0;
img_BGsub_vasc_bw = img_BGsub_vasc;
img_BGsub_vasc_bw(img_BGsub_vasc_bw > 0) = 1;
if plot_figures == 1
figure(3), imshow(img_BGsub_vasc)
end
vasc_volume(i) = nnz(img_BGsub_vasc)*voxel_size;
for k = 1:10;
theta = (pi/5*(k-1)):0.1:(pi/5*k);
x = radius*cos(theta)+xCenter;
y = radius*sin(theta)+yCenter;
x = [xCenter,x,xCenter];
y = [yCenter, y, yCenter];
mask = poly2mask(x,y,512,512);
img_BGsub_vasc_segment = img_BGsub_vasc.*double(mask);
img_BGsub_organ_segment = img_BGsub_organ.*double(mask);
if max(max(img_BGsub_organ_segment)) == 0;
segment_present{i}(k) = 0;
vasc_volume_segment{i}(k) = NaN;
B.4 MATLAB code to quantify vascular area in a DICOM images 121
mean_intensity_segment{i}(k) = NaN;
else segment_present{i}(k) = 1;
vasc_volume_segment{i}(k) = nnz(img_BGsub_vasc_segment)*voxel_size;
mean_intensity_segment{i}(k) =
mean(mean(img_BGsub_vasc_segment(img_BGsub_vasc_segment~=0)));
tf = isnan(mean_intensity_segment{i}(k));
if tf == 1
mean_intensity_segment{i}(k) = 0;
end
end
end
max_segment{i} = max(mean_intensity_segment{i});
min_segment{i} = min(mean_intensity_segment{i});
if min_segment{i} ~= 0
overall_heterogeneity(i) = max_segment{i}/min_segment{i};
elseif max_segment{i} == 0;
overall_heterogeneity(i) = 1;
else overall_heterogeneity(i) = max_segment{i};
end
for l = 1:9
if segment_present{i}(l) == 1 && segment_present{i}(l+1) == 1
if mean_intensity_segment{i}(l)
~= 0 && mean_intensity_segment{i}(l+1) ~= 0
f{i}(l) = mean_intensity_segment{i}
(l)/mean_intensity_segment{i}(l+1);
elseif mean_intensity_segment{i}(l)
~= 0 && mean_intensity_segment{i}(l+1) == 0
f{i}(l) = mean_intensity_segment{i}(l);
elseif mean_intensity_segment{i}(l)
== 0 && mean_intensity_segment{i}(l+1) ~= 0
f{i}(l) = mean_intensity_segment{i}(l+1);
elseif mean_intensity_segment{i}(l)
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== 0 && mean_intensity_segment{i}(l+1) == 0
f{i}(l) = 1;
end
if f{i}(l) < 1
f{i}(l) = 1/f{i}(l);
end
else f{i}(l) = NaN;
end
end
if segment_present{i}(10) == 1 && segment_present{i}(1) == 1
if mean_intensity_segment{i}(10)
~=0 && mean_intensity_segment{i}(1) ~=0
f{i}(10) = mean_intensity_segment{i}
(10)/mean_intensity_segment{i}(1);
elseif mean_intensity_segment{i}(10)
~=0 && mean_intensity_segment{i}(1) ==0
f{i}(10) = mean_intensity_segment{i}(10);
elseif mean_intensity_segment{i}(10)
==0 && mean_intensity_segment{i}(1) ~=0
f{i}(10) = mean_intensity_segment{i}(1);
elseif mean_intensity_segment{i}(10)
==0 && mean_intensity_segment{i}(1) ==0
f{i}(10) = 1;
end
if f{i}(10) < 1
f{i}(10) = 1/f{i}(10);
end
else f{i}(10) = NaN;
end
segment_heterogeneity(i) = nansum(f{i})/sum(~isnan(f{i}));
end
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total_organ_volume = sum(organ_volume(start_frame:end_frame));
total_vasc_volume = sum(vasc_volume(start_frame:end_frame));
total_mean_segment_heterogeneity
= nanmean(segment_heterogeneity(start_frame:end_frame));
total_overall_heterogeneity_mean
= nanmean(overall_heterogeneity(start_frame:end_frame));
for o = 1:10
count(o) = 0;
f2_sum(o) = 0;
for n = start_frame:end_frame-1
if segment_present{n}(o) == 1 && segment_present{n+1}(o) == 1
if mean_intensity_segment{n}(o)
~= 0 && mean_intensity_segment{n+1}(o) ~= 0;
f2{n}(o) = mean_intensity_segment{n}(o)/
mean_intensity_segment{n+1}(o);
elseif mean_intensity_segment{n}(o)
~= 0 && mean_intensity_segment{n+1}(o) == 0;
f2{n}(o) = mean_intensity_segment{n}(o);
elseif mean_intensity_segment{n}(o)
== 0 && mean_intensity_segment{n+1}(o) ~= 0;
f2{n}(o) = mean_intensity_segment{n+1}(o);
elseif mean_intensity_segment{n}(o)
== 0 && mean_intensity_segment{n+1}(o) == 0;
f2{n}(o) = 1;
end
if f2{n}(o) < 1
f2{n}(o) = 1/f2{n}(o);
end
count(o) = count(o) + 1;
f2_sum(o) = f2_sum(o) + f2{n}(o);
else f2{n}(o) = NaN;
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end
end
longitudinal_segment_heterogeneity(o) = f2_sum(o)/count(o);
end
total_longitudinal_heterogeneity
= sum(longitudinal_segment_heterogeneity)/10;
segment_heterogeneity = segment_heterogeneity’;
overall_heterogeneity = overall_heterogeneity’;
longitudinal_segment_heterogeneity = longitudinal_segment_heterogeneity’;
Results_all_frames(1) = total_organ_volume;
Results_all_frames(2) = total_vasc_volume;
Results_all_frames(3) = total_vasc_volume/total_organ_volume;
Results_all_frames(4) = total_mean_segment_heterogeneity;
Results_all_frames(5) = total_overall_heterogeneity_mean;
Results_all_frames(6) = total_longitudinal_heterogeneity;
save([’Results.mat’], ’segment_heterogeneity’, ’overall_heterogeneity’,
’longitudinal_segment_heterogeneity’,’Results_all_frames’);
B.5 MATLAB code to quantify vascular heterogeneity in
DICOM images
B.5.1 Build output file
Contents
• Load files
• find the 99.5th percentile
• Load Large vasculature con dicom stack
• Load microvasculature con dicom stack
• Load delayed perfusion con dicom stack
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• calculate normalized areas
• save results
Load files
thresh1 = 800; %emperically determinde threshold for subtracting background
user_path_noncon = uigetdir(...
’/Users’...
, ’Select DICOM Directory for Non-contrast images’);
user_path_large = uigetdir(...
’/Users/’...
, ’Select Large Vasc DICOM directory’);
user_path_micro = uigetdir(...
’/Users/’...
, ’Select Micro Vasc DICOM directory’);
user_path_delayed = uigetdir(...
’/Users/’...
, ’Select delayed perfusion DICOM directory’);
find the 99.5th percentile
statBar = waitbar(0,’Processing non-contrast images’); %initialize progress bar
cd(user_path_noncon)
ctNC = load(’ct.mat’);
ctNC = ctNC.ct;
%Create bw image
ctNC.im = uint16(ctNC.im);
%Convert to 16bit integer format - should be fixed in dicom_load.m
ctNC.bw = imbinarize(ctNC.im,thresh1/(2^16));
%Value previously determined empirically
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for ii = 1:size(ctNC.bw,3)
ctNC.bw_filt(:,:,ii) = bwareafilt(ctNC.bw(:,:,ii),1);
%Select largest feature in each frame
%note this breaks down at the Z dimension edges if there is free contrast
ctNC.bw_filt(:,:,ii) = imfill(ctNC.bw_filt(:,:,ii),’holes’);
end
x = ctNC.im;
z = reshape(x, 1,[]);
z(z < thresh1) = [];
figure;histogram(z)
upperThresh = double(prctile(z,99.5));
Load Large vasculature con dicom stack
waitbar(0.33, statBar ,’Processing Large Vasculature images’);
cd(user_path_large)
ctL = load(’ct.mat’);
ctL = ctL.ct;
%Create bw image
ctL.im = uint16(ctL.im);
%Convert to 16bit integer format - should be fixed in dicom_load.m
ctL.bw = imbinarize(ctL.im,800/(2^16));
%Value previously determined empirically
ctL.bw_con = imbinarize(ctL.im,upperThresh/(2^16));
totalArea = 0;
totalAreaConLarge = 0;
for ii = 1:size(ctL.bw,3)
ctL.bw_filt(:,:,ii) = bwareafilt(ctL.bw(:,:,ii),1);
%Select largest feature in each frame
%note this breaks down at the Z dimension edges if there is free contrast
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ctL.bw_filt(:,:,ii) = imfill(ctL.bw_filt(:,:,ii),’holes’);
totalArea = totalArea + sum(sum(ctL.bw_filt(:,:,ii)));
totalAreaConLarge = totalAreaConLarge + sum(sum(ctL.bw_con(:,:,ii)));
end
Load microvasculature con dicom stack
waitbar(0.66, statBar ,’Processing micro-vasculature images’);
cd(user_path_micro)
ctM = load(’ct.mat’);
ctM = ctM.ct;
%Create bw image
ctM.im = uint16(ctM.im);
%Convert to 16bit integer format - should be fixed in dicom_load.m
ctM.bw = imbinarize(ctM.im,800/(2^16));
%Value previously determined empirically
ctM.bw_con = imbinarize(ctM.im,upperThresh/(2^16));
totalArea2 = 0;
totalAreaConMicro = 0;
for ii = 1:size(ctM.bw,3)
ctM.bw_filt(:,:,ii) = bwareafilt(ctM.bw(:,:,ii),1);
%Select largest feature in each frame
%note this breaks down at the Z dimension edges if there is free contrast
ctM.bw_filt(:,:,ii) = imfill(ctM.bw_filt(:,:,ii),’holes’);
totalArea2 = totalArea2 + sum(sum(ctM.bw_filt(:,:,ii)));
totalAreaConMicro = totalAreaConMicro + sum(sum(ctM.bw_con(:,:,ii)));
end
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Load delayed perfusion con dicom stack
waitbar(0.85, statBar ,’Processing delayed perfusion images’);
cd(user_path_delayed)
load(’ct.mat’)
ctD = load(’ct.mat’);
ctD = ctD.ct;
%Create bw image
ctD.im = uint16(ctD.im);
%Convert to 16bit integer format - should be fixed in dicom_load.m
ctD.bw = imbinarize(ctD.im,800/(2^16));
%Value previously determined empirically
ctD.bw_con = imbinarize(ctD.im,upperThresh/(2^16));
totalArea3 = 0;
totalAreaConDelayedPerfusion = 0;
for ii = 1:size(ctD.bw,3)
ctD.bw_filt(:,:,ii) = bwareafilt(ctD.bw(:,:,ii),1);
%Select largest feature in each frame
%note this breaks down at the Z dimension edges if there is free contrast
ctD.bw_filt(:,:,ii) = imfill(ctD.bw_filt(:,:,ii),’holes’);
totalArea3 = totalArea3 + sum(sum(ctD.bw_filt(:,:,ii)));
totalAreaConDelayedPerfusion
= totalAreaConDelayedPerfusion + sum(sum(ctD.bw_con(:,:,ii)));
end
calculate normalized areas
waitbar(1, statBar ,’Calculating normalized areas’);
vol_kidney = (totalArea + totalArea2)/2;
vol_vasc = totalAreaConMicro;
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vol_largeVasc = totalAreaConLarge;
vol_microVasc = totalAreaConMicro - totalAreaConLarge;
vol_delayedPerfusion = totalAreaConDelayedPerfusion - totalAreaConLarge;
vol_normalized_vasc = vol_vasc / vol_kidney;
vol_normalized_largeVasc = vol_largeVasc / vol_kidney;
vol_normalized_microVasc = vol_microVasc / vol_kidney;
vol_normalized_delayedPerfusion = vol_delayedPerfusion / vol_kidney;
save results
waitbar(1, statBar ,’saving results’);
output(1).im_noncon = ctNC(1).im;
output(1).im_largeVasculature = ctL(1).im;
output(1).im_microVasculature = ctM(1).im;
output(1).im_delayedPerfusion = ctD(1).im;
output(1).bw_totalArea = ctM(1).bw_filt;
output(1).bw_largeVasculature = ctL(1).bw_con;
output(1).bw_microVasculature = ctM(1).bw_con;
output(1).bw_delayedPerfusion = ctD(1).bw_con;
output(1).thresh1 = thresh1;
output(1).thresh2 = upperThresh;
output(1).user_path_large = user_path_large;
output(1).user_path_micro = user_path_micro;
output(1).user_path_noncon = user_path_noncon;
output(1).user_path_delayed = user_path_delayed;
output(1).vol_normalized_vasc = vol_normalized_vasc;
waitbar(1, statBar ,’done’);
pause(0.1); close(statBar);
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B.5.2 Analyze cortex heterogeneity
Contents
• Create binary images
• Generate histograms
[file, user_path_output] = uigetfile
(’*.mat’, ’Please Select the output.mat file’);
load(fullfile(user_path_output,file)); img = output(1).im_largeVasculature;
% inputs
start_frame = 1;
end_frame = 160;
single_frame = idivide( (end_frame+start_frame) , int16(2));
%currently choosing the midpoint between start and end frames
distance = 8;
thickness = 8;
show_fig = 1;
% outputs: whole_kidney_cortex_pixels, single_frame_kidney_cortex_pixels
Create binary images
BG_thresh = 800;
img_bw = imbinarize(img, BG_thresh/(2^16));
%Value previously determined empirically
img_bw_filt = false(size(img_bw));
img_bw_cortex = false(size(img_bw));
for ii = start_frame:end_frame %1:size(img_bw, 3)
img_bw_filt(:,:,ii) = bwareafilt(img_bw(:,:,ii),1);
%Select largest feature in each frame
%note this breaks down at the Z dimension edges if there is free contrast
img_bw_filt(:,:,ii) = imfill(img_bw_filt(:,:,ii),’holes’);
%figure; imshow(img_bw_filt(:,:,ii));
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se = strel(’disk’, distance, 4);
img_bw_cortex_outer = imerode(img_bw_filt(:,:,ii), se);
se = strel(’disk’, thickness, 4);
img_bw_cortex_inner = imerode(img_bw_cortex_outer, se);
if(show_fig)
[B,~] = bwboundaries(img_bw_cortex_outer);
[B2,~] = bwboundaries(img_bw_cortex_inner);
figure(1), imshow(img(:,:,ii), []); title(strcat(’slice #’, num2str(ii)));
hold on
for k = 1:length(B)
boundary = B{k};
plot(boundary(:,2), boundary(:,1), ’r’, ’LineWidth’, 1)
end
for k = 1:length(B2)
boundary = B2{k};
plot(boundary(:,2), boundary(:,1), ’r’, ’LineWidth’, 1)
end
hold off
end
bw_cortex = img_bw_cortex_outer;
bw_cortex(img_bw_cortex_inner) = false;
img_bw_cortex(:,:,ii) = bw_cortex;
%figure; imshow(img_bw_cortex);
end
Generate histograms
whole_kidney_cortex_pixels = img(img_bw_cortex);
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figure; histogram(whole_kidney_cortex_pixels);
title(’Cortex histogram’)
grid on;
x = img(:,:,single_frame);
single_frame_kidney_cortex_pixels = x(img_bw_cortex(:,:,single_frame));
figure; histogram(single_frame_kidney_cortex_pixels);
title(strcat(’Cortex histogram for slice #’, num2str(single_frame)))
grid on;
